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ABSTRACT 
Human respiratory syncytial virus (RSV) is responsible for several million hospitalizations 
and 199,000 deaths in young children worldwide.  In 1960s clinical trials, children who were 
vaccinated with alum-adjuvanted, formalin-inactivated whole RSV (FI-RSV) developed 
vaccine-enhanced respiratory disease after RSV infection, resulting in tragic vaccine failure. 
There is no licensed RSV vaccine. The goals of my PhD thesis studies were to better understand 
pulmonary inflammation in vaccinated animals and to develop safe and effective RSV vaccines.  
In the first project, I investigated the vaccine efficacy of RSV fusion (F) proteins in a 
soluble form or on virus-like particle (F-VLP). F VLP preferentially elicited T helper type 1 (Th1) 
immune responses whereas alum-adjuvanted F protein induced Th2 responses. Despite lung viral 
clearance, F protein immune mice displayed weight loss and lung histopathology and high mucus 
production and eosinophils. In contrast, prime or prime-boost of F VLP prevented eosinophils’ 
infiltration and vaccine-associated disease. An intrinsic property of F VLP to prime Th1 type 
immune responses appears to prevent RSV vaccine-enhanced disease after RSV challenge.  In the 
second project, I investigated the adjuvant effects of monophosphoryl lipid A (MPL, a TLR4 
ligand) and oligodeoxynucleotide CpG (CpG, a TLR9 ligand) on vaccine-enhanced respiratory 
disease after F protein prime vaccination and RSV challenge in infant and adult mice.  
Combination CpG+MPL adjuvant in RSV F protein prime vaccination of infant and adult age mice 
promoted the induction of Th1 type immune responses, and lung viral clearance after challenge.  
Importantly, CpG+MPL adjuvant plus F protein priming of mice was effective in preventing 
inflammatory lung histopathology and Th2 cytokine-expressing CD4 T cell responses after RSV 
challenge. In the third project, I found that inactivated and detergent-split RSV vaccines exposed 
neutralizing epitopes at higher levels than inactivated whole virus. Split RSV vaccination of mice 
induced less lung histopathology compared to FI-RSV after RSV challenge.  Split RSV 
vaccination of mice with CpG and MPL adjuvants was found to be most effective in increasing 
Th1 type IgG2a antibodies, neutralizing activity, and lung viral clearance as well as modulating 
immune responses to prevent pulmonary histopathology after RSV vaccination and challenge.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDEX WORDS: Respiratory Syncytial Virus, Virus like particle, Fusion (F) protein, Detergent-
split RSV vaccines, Vaccine enhanced-disease, T helper type 1 and 2 CD4 T cell 
response, Histopathology, Adjuvants. 
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1 INTRODUCTION  
 
 
1.1 Human respiratory syncytial Virus (RSV)  
Human respiratory syncytial virus (RSV) is an enveloped virus containing a negative 
sense strand RNA genome and belongs to the Pneumoviridae family. RSV has three integral 
membrane proteins, fusion (F), glycoprotein (G), and small hydrophobic (SH). The G protein 
helps viral attachment to the host cell, during the processing of F protein for fusion. The SH 
protein forms a pentameric ion channel (1). To develop the antiviral drug against RSV infection, 
RSV F and G proteins are mainly targeted by neutralizing antibodies (1).  RSV infection is 
responsible for annual outbreaks of lower respiratory tract disease in infants and elderly, 
resulting in global incidence of 33 million cases in children younger than 5 years old, an 
estimated 3.4 million hospitalizations, and up to 199,000 deaths (2).  In the US, RSV infection is 
associated with 14,000 annual adults age 65 years and older deaths caused by RSV and 177,000 
hospitalizations (3). Older adults are also highly susceptible to significant disease and mortality 
due to RSV infection (3).  RSV is antigenically stable, but most adults are re-infected every 
seasonal period, suggesting that that natural immunity is not long-lasting (4, 5). There is no RSV 
vaccine licensed.   
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1.2 RSV vaccine-enhanced respiratory disease and vaccine adjuvants 
1.2.1 Formalin-inactivated whole RSV vaccine (FI-RSV) enhanced respiratory disease after 
infection 
In the 1960s clinical trials, infants and children who were vaccinated with alum-adjuvanted 
formulation of formalin-inactivated whole RSV (FI-RSV) developed vaccine enhanced respiratory 
disease upon natural infection during epidemic winter season (6). To better understand this 
abnormal disease of alum adjuvant FI-RSV vaccine enhancement of pulmonary histopathology 
has been recaptured in various animal models including mice (7, 8), cotton rats (9), cattle (10), 
and African green monkeys (11).  and monkeys (11). Subsequent animal model studies have 
implicated roles for innate immune response with CD4 T cells, eosinophils and neutralizing 
antibodies related in enhanced RSV disease. T helper type 2 (Th2)-biased immune responses are 
mostly responsible for airway hyperreactivity and mucus hypersecretion. In contrast, the Th1-
associated cytokine TNF-α was necessary to mediate airway obstruction and weight loss (12). 
However, the underlying immunological mechanisms responsible for the enhanced respiratory 
disease and other disease manifestations associated with FI-RSV vaccine-enhanced disease have 
not been fully understood yet. 
 
1.2.2 RSV F soluble protein vaccines 
 Human RSV proteins are transmembrane and use to control lung viral titers as 
immunogenic and effective glycoprotein vaccines (13-15). RSV F glycoprotein is one of 
transmembrane surface proteins that are believed to be the most important vaccine antigen because 
of integral to infectivity of RSV. Additional studies reported that these RSV protein vaccines 
develop enhanced pulmonary pathology after several months of vaccination after RSV challenge 
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in cotton rats (7, 14).  RSV F protein subunit vaccines are under clinical investigation, targeting to 
older populations and high-risk children or maternal immunization. Alum adjuvanted purified F 
protein vaccines were tested in early clinical phase I and II trials of different age groups including 
healthy adults, children over 12 months of age, older persons, and pregnant women (16).  A phase 
II trial of alum-adjuvanted F protein vaccines in seropositive children showed an increase in 
neutralizing titers but no reduction in the incidence of RSV infections (17, 18). F protein 
nanoparticles-based vaccines are advanced to Phase III trials (18, 19). The pre-fusion F protein 
vaccine candidates are under Phase I and II clinical studies (18, 19).  Although RSV F is being 
developed as an important subunit vaccine candidate, its vaccination is often associated with a T 
helper type 2 (Th2) immune marker.  F protein vaccines were reported to cause enhanced lung 
histopathology in animal models (14, 20-23). Therefore, RSV vaccine-enhanced disease is a major 
concern in the development of an effective and safe RSV vaccine.  
 
1.2.3 Virus like particle (VLP) vaccines 
Virus-like particle (VLP) is non-replicating and noninfectious but can represent a 
morphological and structural similarity of an enveloped virus such as RSV. Newcastle disease 
virus (NDV) structural proteins (NP, M) were co-expressed to produce VLP vaccines containing 
the ectodomains of RSV F and G proteins in a chimeric fusion to the transmembrane and 
cytoplasmic tail of the NDV membrane proteins (24, 25).  NDV VLP vaccines containing RSV F 
and G ectodomains provided protection against RSV by inducing long-lived RSV neutralizing 
antibodies without lung inflammation upon RSV challenge in mice (24, 26, 27) and cotton rats 
(28O). Our previous studies demonstrated the immunogenicity and efficacy of RSV F VLP 
produced in insect cells by co-expressing the influenza virus M1 matrix protein. RSV F VLP was 
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found to be immunogenic and confer protection against RSV (29, 30).  F VLP vaccine is unique 
in conferring protection against RSV without causing lung inflammation after RSV challenge (31).     
It remains unknown whether prime only vaccination with F VLP would confer protection 
against RSV and how F protein vaccines presented in VLP or soluble platforms result in different 
outcomes in terms of preventing vaccine-enhanced pulmonary histopathology after RSV 
challenge.  This study has focused on addressing immunological mechanisms underlying these 
important questions.  
 
1.2.4 Split RSV vaccines  
Preparation of sub-virion vaccines by ‘splitting’ inactivated influenza viruses has been 
most commonly used in seasonal vaccination since the dissolution of the lipid envelope allows 
retention of immunogenicity with reduction in reactogenicity (32). Most influenza vaccines 
manufactured since the 1970s have been ‘split’ preparations. An intact viral membrane is required 
for infectivity of enveloped viruses, and disruption of the viral envelope adds further assurance of 
viral inactivation. Clinical trials comparing whole-virus and split-influenza vaccines demonstrated 
that these split influenza vaccines retain the immunogenic properties of the viral proteins but they 
have lower reactogenicity than whole-virion vaccines (33-35). In contrast to many studies on 
whole FI-RSV, the antigenicity and immunogenicity of inactivated split RSV vaccines remain 
unknown. It is of high priority to develop a new RSV vaccine platform and adjuvant enhancing 
the vaccine efficacy and avoiding enhanced pulmonary histopathology after RSV infection. A 
previous study demonstrated that intranasal immunization of mice with nanoemulsion-adjuvanted, 
inactivated RSV vaccine provided protection against RSV challenge by promoting Th1 and Th17 
responses and no evidence of Th2 mediated immunopotentiation (36).   
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1.3 Effects of vaccine adjuvants on RSV vaccine efficacy 
Successful vaccination is the most effective measure to prevent disease against future 
pathogens. In general, non-replicating subunit vaccines are safer than live attenuated vaccines but 
typically require adjuvants for successful antigen-specific immune responses. To improve 
induction of immune responses in vivo is typically performed with subunit protein vaccine antigens 
administered together with external vaccine adjuvants, such as the most conventional aluminum 
salts (alum), oil-in-water emulsion (MF59), and polysaccharides-based components (Q21, delta-
inulin).  Vaccine adjuvants based on Toll-like receptor (TLR) ligands have been developed and 
used as standalone or in combinations such as alum plus TLR4 agonist (AS04). 
Oligodeoxynucleotides containing unmethylated cytosine-phosphate-guanosine (CpG) motifs, a 
TLR-9 agonist, promote the induction of Th1 immune responses to RSV F or killed RSV 
vaccination (22, 37, 38). However, details on pulmonary inflammation and RSV disease after RSV 
challenge were not investigated in CpG adjuvanted RSV vaccinated mice.  Monophosphoryl lipid 
A (MPL) is an attenuated version of lipopolysaccharide TLR4 agonist (39) and licensed for use in 
human vaccines (40).  We found that combination CpG and MPL adjuvants at low doses 
effectively promoted the efficacy of split influenza vaccines (41). However, the roles of the 
adjuvants in the efficacy and safety of RSV vaccination is still poorly defined. 
 
1.3.1 Aluminium hydroxide (Alum) adjuvant 
 Alum adjuvant has a long history of usage and is used in human and animal with split and 
subunit vaccines as an adjuvant. Previous studies suggested the potency of alum adjuvant by 
forming T helper type 2 (Th2) antigen response in the administration sites and granting the 
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persistence and prolonged release of antigens (41). Inducing Th2 cytokines control the 
differentiation of Th2 cells and related B cells to generate Th2-associated antibodies (IgG1) and 
allergic immune responses. Also, alum was shown to raise proinflammtory mediators including 
interleukin (IL)-1β, CC-chemokine ligand 2 (CCL2; MCP1), CCL11 (eotaxin), histamine and IL-
5 as well as neutrophils, eosinophils, inflammatory monocytes, myeloid dendritic cells (DCs), and 
plasmacytoid DCs. However, alum adjuvant would not be highly effective in the efficacy of 
subunit vaccines targeting intracellular viral pathogens. 
 
1.3.2. Monophosphoryl lipid A (MPL) adjuvant 
MPL, a detoxified bacterial lipopolysaccharide, is a synthetic lipid A that is a weak TLR4 
agonist. MPL is licensed and has demonstrated a safe profile in two vaccines when co-administered 
with different RSV vaccine preparations as a vaccine adjuvant. It was previously reported that 
immunization of cotton rats with the original lot 100 FI-RSV, formulated with MPL, blunted both 
the cytokine storm and the enhanced lung pathology elicited by subsequent RSV infection, but did 
not inhibit viral replication in the lungs. Administration of vaccines containing MPL has resulted 
in high antigen-specific antibody and CD4+ T-cell responses in preclinical and clinical studies 
(42) (43). Also, MPL enhanced the ability of macrophages and B cells to sensitize naive T cells 
and to promote T cell development to Th1 and Th2 type cells (44). 
 
1.3.3 Oligodeoxynucleotide containing unmethylated CpG motifs (CpG adjuvant) 
Synthetic oligodeoxynucleotides containing unmethylated cytosine-phosphate-guanosine 
(CpG), a TLR-9 agonist, are known to activate Th1 immune responses to RSV F or killed RSV 
vaccination (22, 37, 38) but no details on CpG adjuvant effects on lung inflammation and RSV 
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disease after vaccination and RSV challenge were reported. Human plasmacytoid dendritic cells 
and B cells express TLR 9 and can be activated to enhance the production of Th1 response and 
proinflammatory cytokines such as IL-6 upon CpG stimulation.  CpG also improves the function 
of professional antigen-presenting cells (APC) and boost the generation of humoral and cellular 
vaccine-specific immune responses as using vaccine adjuvants. The adjuvant properties of CpG 
are observed when administered either systemically or mucosally and persist in 
immunocompromised hosts. Preclinical studies indicate that CpG improve the activity of vaccines 
targeting infectious diseases and cancer (45, 46). 
 
1.4 Purpose of PhD thesis study 
Enhanced respiratory disease is characterized by severe pulmonary inflammation leading 
to bronchitis and pneumonia after RSV infection. A phenomenon of inducing enhanced respiratory 
disease still remains poorly understood after alum-adjuvanted FI-RSV or subunit protein 
vaccination and RSV infection. The purpose of my overall PhD thesis studies is to better 
understand the RSV-induced pulmonary inflammation in vaccinated animals, vaccine adjuvant 
effects on RSV vaccine efficacy, and to develop safe and effective RSV vaccines. The findings 
during my PhD study provide new information and insight into the desirable types of immune 
responses that induce neutralizing activity and control viral replication but prevent RSV vaccine 
enhanced pathology. RSV fusion (F) protein attached VLP (F VLP), combined CpG+MPL 
adjuvanted F protein and split RSV vaccines are suggested to be a protective vaccine target 
although its efficacy and safety concerns remain not well understood.  
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2 EXPERIMENT 
 
2.1 Cells, Virus and Vaccine formulation with adjuvants.  
 
Hep2 and Spodoptera frugiperda 9 (Sf9) insect cells were obtained from American Type 
Culture Collection (ATCC). Hep2 cells were grown in DMEM supplemented with 5% fetal bovine 
serum and penicillin/streptomycin antibiotics. The RSV A2 was provided from Dr. Martin Moore 
(Emory University, GA) and propagated in HEp 2 Cells (American Type Culture Collection).  Sf9 
insect cells were grown in serum free SF900 II medium from Gibco-BRL and used for amplifying 
recombinant baculoviruses (rBVs) expressing RSV F proteins and F VLP vaccine production.  For 
RSV F VLP vaccine production, insect cells were co-infected with rBVs expressing RSV F 
proteins (RSV A2 strain) and influenza virus M1 matrix protein, and F VLP was purified from Sf9 
culture supernatants using ultracentrifugation and characterized as previously described (29). The 
antigenic integrity and epitopes’ exposure of FI-RSV, split RSV, F protein, and F VLP vaccines 
was determined by ELISA using post-F specific (131-2a monoclonal antibody purchased from 
Millipore) and pre-F specific (5C4) monoclonal antibodies. The RSV A2 F glycoprotein was 
obtained from Biodefense and Emerging Infections Research Resources (NR-28908, BEI 
Resources, Manassas, VA). A recombinant form of soluble F glycoprotein with C-terminal 
histidine tag was expressed by transfection of 293F cells with a plasmid encoding a codon-
optimized F gene and purified from the cell culture supernatant using nickel chromatography. 
Antigenic analysis indicates that the F protein used in this study is likely to form a post-fusion 
conformation. For FI-RSV preparation, RSV (A2) infected Hep2 cells were cultured by media for 
3 to 5 days at 37°C. The cells and media were collected to cold chilled tubes from the RSV infected 
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Hep2 cell culture flask. The infected cells were sonicated and clarified by centrifugation (2000 x 
g, 10min, 4°C). Collected supernatants were mixed with filtrated formalin to final concentration 
(1:4000 vol/vol of 37% formalin) and incubated for 3 days at 37°C with stirring. Inactivated RSV 
was precipitated from formalin treated supernatants by ultra-centrifugation (80,000 – 100,000 x g, 
1hr, 4°C). The RSV precipitates were suspended with filtered 1xPBS for storage and kept at -80C. 
Also, formalin inactivated split RSV was prepared by using detergent; Triton-x 100 and purified 
by sucrose gradient after FI-RSV preparation. All vaccines were stored at -80°C until used in this 
study. Adjuvant Alum (Sigma Aldrich, St. Louis, MO), MPL (Sigma Aldrich, St. Louis, MO), or 
CpG (oligodeoxynucleotide 1826, 5'-TCC ATG ACG TTC CTG ACG TT-3', DNA Technologies), 
was mixed with 0.1 µg F protein or 5 µg split RSV vaccine and used to vaccinate the mice. 
 
2.2 Animals, Immunization and RSV challenge.  
To investigate the RSV F VLP and RSV F protein vaccine efficacy, BALB/c mice (n=5, 6-8 weeks 
old males and females, Charles River Laboratories, Inc.) were intramuscularly (i.m.) primed (a 
single dose) with 10 μg of F VLP, 0.1 μg or 0.3 μg of F protein in the Alum (50 μg) adjuvant, and 
phosphate buffered saline (PBS, naïve control). Additional sets of the BALB/c groups (n=5) were 
prime-boost vaccinated with the same vaccines at a 3-week interval. Blood samples were collected 
at 3 weeks after each vaccination. Naïve control, F-VLP, F protein immunized mice were 
intranasally (i.n.) infected with 5 x 10⁵ PFU of RSV A2 under isofluorane anesthesia to determine 
the efficacy of protection and vaccine-enhanced disease 3 to 4 weeks after vaccination.  
For adjuvant effect with RSV F soluble protein, BALB/c mice (n=5, Charles River Laboratories, 
Inc.) were intramuscularly (i.m.) primed (a single dose) with 0.1 μg of F protein only or in the 
presence of adjuvant Alum (50 µg), MPL (1 µg), CpG (4 µg), MPL (1 µg) + CpG (4 µg), or 
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phosphate buffered saline (PBS, naïve control). The infant mice were 2 weeks old and adult mice 
were 6 to 8weeks old at the time of priming immunization.  
For new strategy of RSV vaccines in young mice, 2weeks old female BALB/c mice (n = 5; Charles 
River Laboratories, Inc.) were single immunized intramuscularly (i.m.) with 2ug of FI-RSV or 5ug 
of split RSV with/without adjuvant Alum (50µg), CpG (1µg) MPL (4µg), CpG (1µg) + MPL (4µg) 
adjuvant, and phosphate buffered saline (PBS, naïve control). For immunogenicity study, blood 
samples were collected from individual mice at 3 weeks after vaccination. Mice were intranasally 
(i.n.) infected with 3.5 x 10⁵ PFU/ ml of RSV A2 under isoflurane anesthesia to determine the 
efficacy of protection and histopathology at 4 weeks after vaccination. lung, bronchiolar alveolar 
lavage fluids (BALF), mediastinal lymph nodes (MLN), and spleens were collected at 5 days after 
challenge. All animal experimental procedures were approved and performed by following the 
guidelines of Georgia State University Institutional Animal Care and Use Committee. 
 
2.3 ELISA  
Blood samples collected at 3 weeks after prime or boost were used to determine RSV F 
(pre-fusion F and post-fusion F form) specific IgG antibodies by enzyme-linked immunosorbent 
assay (ELISA). Post-fusion F protein (NR- 28908, BEI resources) or pre-fusion conformation 
stabilized protein with DsCav mutations was coated on 96-well plates as an ELISA antigen. The 
pre-fusion F protein with DsCav mutations was kindly provided by Dr. Graham (NIH).  Secondary 
antibodies conjugated with horseradish peroxidase (Southern Biotechnology) were used to detect 
IgG isotype antibodies. The substrate TMB (3, 3′, 5, 5′-tetramethylbenzidine, Sigma Aldrich) was 
treated and stopped with 1M H3PO4. Optical densities (O.D) were read by spectrophotometer 
reader at 450nm. The lung homogenates and bronchoalveolar lavage fluid (BALF) were used to 
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quantify cytokine concentrations by using cytokine ELISA kits of interleukin (IL)-4, IL-5, 
interferon (IFN)-γ, IL-13, and tumor necrosis factor (TNF)-α (eBioscience, SanDiego, CA). 
 
2.4 Lung viral titers and neutralizing antibody assays.  
Serum samples were collected 3 weeks after prime immunization and heat-inactivated at 
56°C for 45 min. In 48-well plates. test sera (starting dilution 1:4) were serially diluted by 2-fold 
increments in cell culture media for a final volume of 50 μL. Each serum serial dilution was mixed 
with 50 μL RSV A2 (200 PFU per well), incubated for 2 h, and added to the monolayer cultures 
of HEp-2 cells (2.5 × 104 cells in each well). Cells plus virus and cells only on wells served as 
controls. After 3 days of incubation at 37°C with 5% CO2, the cell culture medium was removed, 
and the monolayer was fixed with chilled 4% neutral paraformaldehyde. RSV replication was 
visualized by immunostaining with RSV specific F-monoclonal (131-2a) and HRP-labeled 
secondary antibodies. The reciprocal dilutions in log2, inhibiting 50% plaque forming units of 
virus (IC50) was determined for each serum sample. The lower limit of detection (LLOD) of this 
assay is 2 log2.  
Individual lung samples were collected day 5 post challenge and RSV plaque-forming units (PFU) 
for RSV lung viral titers determined using an immuno-plaque assay. RSV control and lung 
homogenates mixed with RSV were incubated on HEp-2 cells for 1h 37°C, 5% CO2 and removed. 
3% agarose mixed with media overlay was added to each well, and cells were incubated for 2 days 
at 37°C. After removed overlay and fixed with 4% formalin, the plaques were detected with anti 
RSV F monoclonal antibody (mAb) (Millipore). 
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2.5 Flow cytometry 
BALF were collected by flushing the lungs with 1 ml of PBS supplemented with protease 
inhibitors using a winged shielded catheter (1.3630 mm, BD Utah) inserted, through an incision, 
in the trachea of euthanized mice.  Lung tissues were isolated by homogenization and used by 
percoll gradient (44 and 67%) centrifugation. The frosted microscope glasses were used for 
harvesting mediastinal lymph nodes (MLN) to suspend the cells. For intracellular cytokine staining 
analysis of T cell responses, lung and BAL cells were stimulated with F peptide (F51-66 CD4 and 
F85-96 CD8 epitopes of RSV F, 4μg/ml) prior to staining of intracellular cytokines, and then the 
cells were fixed and permeabilized according to the manufacturer’s instructions (BD Biosciences). 
Intracellular cytokine and surface makers for T cells were stained with antibodies for IFN-γ, IL-4 
(eBioscience), TNF-α (BioLegend), CD3, CD4, CD8. Infiltrating innate immune cells were 
detected with antibodies for CD11b, CD11c, CD103, F4/80, DX5 Ly6c or Siglec F (BD 
Biosciences). Cellular phenotypes were analyzed with the Becton-Dickinson LSR-II/ Fortessa 
flow cytometer (BD, San Diego, CA) was used and acquired flow cytometry data were analyzed 
by using Flowjo software (Tree Star Inc.). 
 
2.6 Lung histology and inflammation scoring 
Left lungs tissues were harvested on day 5 post challenge and fixed with 10% neutral 
buffered formalin. They were embedded in paraffin in the dorsoventral position. Subsequently, 
sections of tissue blocks were obtained and stained with hematoxylin and eosin (H&E), periodic 
acid–Schiff (PAS), and hematoxylin and congo red (H&CR) (47, 48). Histopathology of lung 
tissue slides were analyzed using a semiquantitative scale (0 to 3) by light microscope. Assigned 
score 0 was the surrounding space which is free or has few infiltrating cells, score 1 contains focal 
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aggregates of infiltrating cells or the structure is cuffed by one definite layer of infiltrating cells, 
score 2 is cuffed by two defined layers of infiltrating cells, and score 3 when structure is cuffed by 
three or more definite layers of infiltrating cells with or without focal aggregates. Randomly 20 
airways were selected to quantify for PAS positive stain with mucin expression area.  H&E stained 
slides were evaluated for inflammatory infiltration and histopathology around peribronchial and/or 
peribronchiolar, perivascular, and interstitial regions(47, 48). The presence of pulmonary 
eosinophilia was quantified by H&CR stain with 400x magnified microscope and flow cytometry 
by using antibodies for eosinophil phenotypic markers (CD11b+, CD11c+, SiglecF).  
 
2.7 Intraperitoneal (IP) injection. 
 BALB/c mice (n=3) were injected with 200 μl of phosphate buffered saline (PBS), F VLP 
(10 μg), F protein (0.1 μg) with alum (50 μg) adjuvants with intraperitoneally. Collected sera were 
analyzed to determine the levels of cytokines and chemokines by using ELISA kits (KC, MCP-1,  
and RANTES; R&D system, IL-4, 5, 13, and IFN-γ; eBioscience) at 1.5, 5, and 20 hours (h) post 
injection. The elicited peritoneal exudate cells were obtained at 24 h post injection by PBS 
flushing. The cells were isolated and analyzed for cellularity of infiltrating cells by flow cytometry. 
Peritoneal exudates were used for detection of cytokines and chemokines. 
 
2.8 Statistical Analysis. 
Statistical differences were performed using GraphPad prim version 5 (Graph Pad software 
Inc, San Diego, CA). Data were analyzed for significance using one-way ANOVA with Tukey’s 
test for multiple comparisons or two-way ANOVA with Bonferroni posttests. The difference was 
considered statistically significant when the P value was less than 0.05. 
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3 CHAPTER1. SOLUBLE F PROTEINS EXACERBATE PULMONARY 
HISTOPATHOLOGY AFTER VACCINATION UPON RESPIRATORY 
SYNCYTIAL VIRUS CHALLENGE BUT NOT WHEN PRESENTED ON VIRUS-
LIKE PARTICLES 
 
3.1 Summary 
Respiratory syncytial virus (RSV) fusion (F) protein is suggested to be a protective vaccine 
target although its efficacy and safety concerns remain not well understood.  We investigated 
immunogenicity, efficacy, and safety of F proteins in a soluble form or on virus-like particle (F-
VLP). F VLP preferentially elicited IgG2a antibody and T helper type 1 (Th1) immune responses 
whereas F protein induced IgG1 isotype and Th2 responses. Despite lung viral clearance after 
prime or prime-boost and then RSV challenge, F protein immune mice displayed weight loss and 
lung histopathology and high mucus production and eosinophils. In contrast, prime or prime-boost 
vaccination of F VLP induced effective protection, prevented infiltration of eosinophils, and 
vaccine- enhanced disease after challenge. This study provides insight into developing an effective 
and safe RSV vaccine candidate.  
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3.2 Result 
3.2.1 RSV F VLP vaccination induces a distinct pattern of IgG isotypes compared to F 
proteins. 
RSV F protein is a common platform of RSV subunit vaccines that are being explored. The 
F VLP and soluble F protein vaccines used in this study were found to be highly reactive to post-
fusion F specific monoclonal antibody (131-2a) recognizing the post fusion F conformation but 
low or no reactivity to pre-fusion F specific 5C4 monoclonal antibody (data not shown).  We 
determined immunogenicity and efficacy of RSV F in a soluble protein form or in a particulate 
VLP after prime or prime-boost vaccination.  Groups of mice were intramuscularly immunized 
with F-VLP (10 μg total proteins, no adjuvant), or F proteins (0.1μg or 0.3μg) with alum adjuvant.  
Both 0.1μg and 0.3μg dose RSV F protein immunization groups induced significantly higher levels 
of RSV F specific IgG1 isotype antibody than F VLP immunized group (Fig. 3.1B).  In contrast, 
F VLP induced IgG2a isotype dominant antibody responses (Fig. 3.1C).  Meanwhile, F protein 
groups showed low or background levels of IgG2a (Fig. 3.1C). Boost dose vaccination induced 
moderate increases in IgG2a and IgG1 isotype antibodies in the F VLP and F protein groups 
respectively. The F VLP group showed significantly higher ratios of IgG2a/IgG1 compared to 
those in F protein groups (Fig. 3.1D). 
Neutralizing antibody is considered a major correlate of protection against RSV. F protein 
and F VLP prime immune sera showed similar neutralizing activities (~9 log2) which were 
significantly higher than those in naïve sera exhibiting the background neutralizing activity of 
approximately 4 log2 (Fig. 3.1E). This neutralizing assay of 50% plaque reduction titers resulted 
in significant increases in a range of 16- to 64-fold higher titers in immunized sera than naïve sera, 
which are statistically significant. Previous studies reported similar ranges of the background 
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neutralizing activity in sera from the naïve mice (25, 29, 30, 49-51), suggesting a limitation in this 
assay. Moderate increases in neutralizing titers (~10 log2) were observed after boost vaccination 
with F VLP or 0.3μg F protein (Fig. 3.1E).   
3.2.2 Mice with RSV F protein vaccination induce protection against viral replication but 
display disease phenotypes. 
Immunized mice were challenged with RSV (5x105 PFU) and body weight changes were 
monitored (Fig. 3.2).  The naïve infection and F protein (0.3 μg) groups displayed approximately 
10% loss of body weight whereas the low dose (0.1 μg) F protein group showed 5-7% body weight 
loss. The F-VLP group exhibited only a slight change in body weight after RSV challenge (Fig. 
3.2A, B). There were no significant differences in body weight between the prime and prime-boost 
groups after challenge.  
Lung tissues were collected from individual mouse after 5 days of challenge and viral loads 
were evaluated with an immunoplaque assay. The naïve infection group had highest viral loads in 
the lungs. Prime or prime-boost vaccinated mice showed significantly lower levels of RSV lung 
viral loads than naïve mice (Fig. 3.2C, D). A better control of viral loads was observed in the boost 
F VLP group than in the F protein groups (Fig. 3.2C, D).   
 
3.2.3 RSV F protein vaccination induces histopathology upon RSV challenge. 
To determine whether RSV F VLP or soluble F protein vaccination induces pulmonary 
inflammation after RSV challenge, we examined lung histology after staining with hematoxylin 
and eosin (H&E), and evaluated inflammation on airway, blood vessels and intestinal space in a 
blind scoring (Fig. 3.3A-E).  The naive control (PBS) group with RSV infection exhibited 
moderate levels of lung inflammation around the airways, blood vessels, and interstitial spaces 
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(Fig. 3.3).  The F protein prime or prime-boost (0.1μg, 0.3μg) groups showed the highest influx of 
inflammatory cells, most severe symptoms of alveolitis, and infiltrates in the airways, blood 
vessels, and interstitial spaces. F VLP prime only or prime-boost immune mice did not display 
lung histopathology after RSV challenge (Fig3.3).  
Excessive mucus production contributes to blocking the airways. Lung tissue sections were 
stained with Periodic acid-Schiff (PAS) to quantify mucus in the randomly selected airways 
epithelium. Consistent with histopathology, F protein prime or prime-boost mice showed the 
highest PAS-positive mucus production with an increasing trend in the high dose (0.3μg) group. 
Naïve mice with RSV challenge showed moderate to low levels of airway mucus production 
whereas mucus was not observed in F VLP immune mice (Fig. 3.4). 
We examined eosinophils infiltration from lung tissue using hematoxylin and congo red 
(H&CR) staining. Significantly infiltrated eosinophils were detected in the airways of 0.1μg or 
0.3μg F protein but not F VLP prime or prime-boost immune mice after RSV challenge (Fig. 3.5A- 
D). The results of eosinophilic histology were consistent with Siglec F+ eosinophils in BALF from 
the F protein groups but not from the F VLP group as determined by flow cytometry (Fig. 3.5E, 
F). Taken together, these results suggest that RSV F soluble protein immunization but not when 
presented on particulate VLPs causes lung histopathology upon RSV challenge. 
 
3.2.4 Biased Th2 cytokines are elicited after F protein vaccination and RSV challenge.  
To investigate the Th1 and Th2 immune responses after immunization and RSV challenge, 
IL-4, IL-5, IL-13 (Th2) and IFN-γ (Th1) cytokines were determined. The F protein (0.1μg, 0.3μg) 
groups showed high levels of Th2 cytokines IL-4, IL-5 and IL-13 in both lung and BALF samples 
collected at day 5 post challenge (Fig. 3.6A-C, E-G). In contrast, high IFN-γ and low Th2 cytokine 
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levels were detected in lung and BALF samples from the F-VLP group, suppressing the induction 
of Th2 type cytokines (Fig. 3.6D and H).  Next, we determined the profile of IFN-γ or IL-4 
secreting CD4 and CD8 T cells in response to stimulation with CD4 (F51-66) and CD8 T (F85-93) 
cell epitopes respectively (Fig. 3.7). Higher levels of IFN-γ secreting CD4 and CD8 T cells were 
observed in lungs (Fig. 3.7A-C, G) and BAL (Fig. 3.7D-F, H) samples from F VLP immune mice 
than those from F protein immune mice. When the ratios of IFN-γ+/IL-4+ CD4 T cells and IFN-
γ+/IL-4+ CD8 T cells were compared, naïve infection and F VLP immune mice resulted in 
significantly higher IFN-γ ratios for both T cells, suggesting dominant Th1 responses (IFN- γ) 
compared to F protein immune mice (Fig. 3.7C, F, I, J). Neutrophils (CD11b+Ly6c+F4/80-) and 
dendritic cells (DCs, CD45+CD11c+MHCII+) were found to be recruited to higher levels in F 
protein immune mice compared to that in the F VLP group after RSV challenge (Fig. 3.7K, L).  
  
3.2.5 F VLP induces transient inflammatory responses. 
To better understand the mechanisms of inducing a distinct pattern of immune responses 
between F VLP and F protein vaccination, we determined innate immune responses at the site of 
injection. Intraperitoneal (IP) injection of F VLP transiently induced chemokines (KC; CXCL1, 
MCP-1) and IFN-γ in sera within 1.5 hours (h) or 5 h, which rapidly waned after 5 h (Fig. 3.8A-
C). Peritoneal exudates displayed high levels of chemokines (RANTES, MCP-1) and IFN-γ at 24 
h post treatment (Fig. 3.8D-F). In contrast, the levels of Th2 cytokines (IL-4, IL-5, and IL-13) 
were higher in peritoneal exudates after injection with F protein but not with F VLP (Fig. 3.8G-I). 
Flow cytometric determination of cellular phenotypes in peritoneal cavity showed that F VLP is 
more effective in recruiting monocytes, neutrophils, and natural killer (NK) cells at the site of 
injection than F protein (Fig. 3.8J-L).  
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Figure 3. 1 RSV-specific IgG isotype antibody levels and neutralizing activity after prime or prime-boost 
vaccination with F VLP or F protein vaccine. 
BALB/c mice (N=5) were immunized with F VLP (10 μg) or F protein (0.1 or 0.3 μg) with alum adjuvant (50μg). 
Sera were collected 3 weeks after prime or prime-boost. (A-C) The IgG isotype levels were determined using F 
protein as antigen for antibody detection. (D) Ratios of IgG2a/IgG1 isotypes. (E) Neutralizing antibody titers.  RSV 
neutralizing activity was determined by an immune-plaque reduction assay and titers were presented as dilution 
factors resulting in 50% reduction in plaque numbers. Results are representative out of two independent experiments 
and presented as mean ± SEM. Statistical significances were performed by one-way ANOVA in GraphPad Prism; 
*** p<0.001, ** p<0.01, * p<0.05 comparing F VLP and F protein groups. Prime; prime only immunization, Boost; 
prime and boost immunization, PBS; unimmunized mice, F VLP; F VLP immunized mice, Fp(0.1) or Fp(0.3); 0.1μg 
or 0.3μg RSV F proteins with alum adjuvant. 
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Figure 3. 2 Body weight changes and lung viral clearance in vaccinated BALB/C mice after RSV challenge. 
 
 
 
 
 
Naïve (PBS only) and vaccinated mice were i.n. challenged with RSV A2 (5 10⁵ PFU) at 4 weeks after prime or 
prime-boost immunization.  (A) Body weight changes in prime immunized mice after RSV challenge. (B) Body 
weight changes in prime-boost immunized mice after RSV challenge. (C) Lung RSV titers after prime 
immunization. RSV titers were determined in individual lungs collected at 5 days after RSV challenge. (D) Lung 
RSV titers after prime-boost immunization. Individual lungs were collected 5 days after RSV challenge. The dotted 
line represents the detection limit. Results were reproducible in two independent sets of animal studies with each 
set n=5 and presented as mean ± SEM. Statistical significances were performed by one-way ANOVA in GraphPad 
Prism; *** P<0.001(C, D), ** p<0.01(D), * P<0.05(D). Naïve R.; Naïve mice + RSV challenge, F VLP; F VLP 
vaccinated mice + RSV challenge, Fp (0.1); F protein 0.1μg + RSV challenge, Fp (0.3); F protein 0.3μg + RSV 
challenge. Independent sets of animal studies with each set n=5 and presented as mean ± SEM. Statistical 
significances were performed by one-way ANOVA in GraphPad Prism; *** P<0.001(C, D), ** p<0.01(D), * 
P<0.05(D). Naïve R.; Naïve mice + RSV challenge, F VLP; F VLP vaccinated mice + RSV challenge, Fp (0.1); F 
protein 0.1μg + RSV challenge, Fp (0.3); F protein 0.3μg + RSV challenge. 
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    Figure 3. 3 Lung histopathology in prime or prime-boost vaccinated mice after RSV challenge.  
 
Lung tissues collected from individual BALB/c mice (N=5) were prime or prime-boost vaccinated mice day 5 post 
challenge. (A, B) Photographs of H&E. Hematoxyline and Eosin (H&E) stained lung tissues were dissected to assess 
histopathology of peribronchiolar and alveolar pneumonia. Scale bars indicate 100 μm. (C-E) The lungs were scored 
using a 1-3 scoring system where 1= minimal pathology and 3 = maximum pathology for the airways (C), interstitial 
spaces (D), blood vessels (E). Results are presented as mean ± SEM. Statistical significances were performed by 
one-way ANOVA in GraphPad Prism; *** P<0.001, ** p<0.01, * p<0.05. Group labels are the same as described 
in the Fig. 2. 
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     Figure 3. 4 Levels of mucus production in the lungs from vaccinated mice after RSV challenge. 
 
Lung tissues were collected from individual BALB/c mouse (N=5) after vaccination and RSV challenge. (A, B) 
Lung tissue histology after staining with Hematoxyline and Congo red (H&CR). Arrows indicate eosinophil 
granulocytes in the individual airways. Scale bars: 20 μm. (C, D) H&CR positive eosinophils were counted under 
the microscopic field and presented in percentages in the prime and prime-boost groups. (E, F) Numbers and flow 
profiles of gated Siglec F+ eosinophils (Siglec F+CD11b+CD11c-F4/80+CD45+) as determined by flow 
cytometry of BAL fluids. Results are presented as mean ± SEM. Statistical significances were performed by one-
way ANOVA in GraphPad Prism; *** P<0.001, * p<0.05. Group labels are the same as described in the Fig. 2. 
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Figure 3. 5 Assessment of eosinophils in the lungs from vaccinated mice after RSV challenge. 
 
 (A, B) Photographs of PAS. Periodic-Schiff (PAS) stained lung tissue were dissected to assess mucus 
production in the bronchiolar and alveolar area. Scale bars: 100μm. (C, D) Percentages of PAS positive airway 
mucus expression. The percentage of PAS positive lung section area in each airway was determined; individual 
airways are shown per group. Results are presented as mean ± SEM. Statistical significances were performed 
by one-way ANOVA in GraphPad Prism; *** P<0.001. Group labels are the same as described in the Fig. 2. 
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Figure 3. 6 Cytokines in the Lung tissue and BALF from prime-boost immune mice after RSV challenge. 
 
(A, B) Lung tissue and BALF were collected from individual mice (N=5) after RSV challenge. Levels of IL-4, IL-
5, IL-13 and IFN-γ cytokines were measured in lung and BALF samples by each corresponding cytokine ELISA 
kits. Results are presented as mean ± SEM. Statistical significances were performed by one-way ANOVA and 
Tukey’s multiple-comparison tests in GraphPad Prism; *** p<0.001, **P<0.01, *p<0.05. Group labels are the same 
as described in the Fig. 2. 
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Figure 3. 7 CD4+, CD8+ T cells secreting Th1 or Th2 cytokines by intracellular cytokine staining, and  
airway infiltrating innate immune cells.  
Lung and BALF cells were collected from prime-boost immunized mice at 5 days after challenge or subjected 
to intracellular cytokine staining. (A, B, D, E, G, H) Intracellular cytokine staining of CD4 and CD8 T cells from 
lungs or BALF by flow cytometry after in vitro stimulation with CD4 T cell F
51−66
 epitope and CD8 T cell F
85-
93
 epitope. (C, F, I, J) Ratios of IFN-γ+/IL4+ CD4 or CD8 T cell number averages from intracellular cytokine 
flow cytometry of lung and BAL samples.  (K) Neutrophils (CD11b
+
Ly6c
+
F4/80
-
) and (L) Dendritic Cells (DCs, 
CD45
+
CD11c
+
MHCII
+
) were analyzed from BALF samples. PBS: Naïve mice with RSV infection. Other groups 
are vaccinated mice as indicated.  The results are presented as averages with standard errors and statistical 
significance was determined using one-way ANOVA with Tukey’s multiple comparison test in GraphPad Prism. 
***, p < 0.001, **p<0.01. Other group labels are the same as described in the Fig. 2. 
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Figure 3. 8. Acute responses of cytokines, chemokines, and cellular infiltrates at the site of injection with F VLP 
or F protein.  
BALB/c mice (n=3) were intra-peritoneally injected with PBS, F VLP, or F protein. (A-C) Kinetics of cytokines 
and chemokine levels in sera from adjuvant injected mice (n=3) mice per group). ***; p<0.001 compared to naïve 
group (PBS only). (D-I) Cytokines and chemokines in peritoneal exudates at 24h after injection. (J) Monocytes: 
CD11b+Ly6c high F4/80+, (K) Neutrophils; CD11b+Ly6c+F4/80-, (L) NK cells; DX5+CD3-, data were shown as 
mean ± SEM. Statistical significances were calculated by 1-way ANOVA and Tukey’s multiple comparison test. 
***; p<0.001 **; p<0.01, and *; p<0.05, as indicated among the groups. Naïve; unimmunized mice, F VLP; F VLP 
immunized mice, F protein; 0.1μg RSV F protein with alum adjuvant. Group information of D-I were same as J-L. 
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3.3 Discussion 
In this study, we compared the pattern of immune responses to F immunogen in VLP and 
in a soluble protein, and their resulting efficacy and lung inflammation after RSV challenge.  F 
VLP or F protein vaccination induced IgG2a and IgG1 isotype dominant antibody responses 
respectively, representing Th1 and Th2 type immune patterns. Prime or prime-boost immunization 
with F VLP and F protein vaccines showed comparable RSV neutralizing activity and was 
effective in controlling lung viral loads after RSV challenge, which is consistent with a previous 
study reporting moderate increases in IgG titers after boost with FI-RSV or purified F protein (14).  
Nonetheless, there were striking differences in pulmonary histopathology, mucus production, and 
eosinophilia as well as body weight loss of RSV disease between the F VLP and F protein vaccine 
groups.  
Since RSV vaccine-enhanced disease was first observed during 1960s clinical trials of FI-
RSV vaccines (6), numerous efforts have been made to develop RSV vaccines that can avoid 
vaccine-enhanced pulmonary histopathology.  RSV F, G (attachment), and chimeric FG protein 
subunit vaccines were previously shown to cause vaccine-enhanced pulmonary histopathology in 
mouse and cotton rat animal models (14, 22, 23). Bronchiolar histopathology and pulmonary 
polymorphonucleocytes infiltration appeared to be evident after vaccination with Vac-F and RSV 
challenge in mice (52, 53) but less likely in cotton rats (54), suggesting a greater tendency for mice 
to develop RSV-vaccine enhanced disease. Viral-vectored RSV vaccines are likely to mimic 
natural infection inducing innate and adaptive responses. Modified vaccinia virus Ankara and 
simian adenovirus expressing RSV proteins were immunogenic and safe in healthy adults (phase 
I), warranting further clinical evaluation of efficacy (55). The recombinant Sendai virus, a mouse 
type I parainfluenza virus expressing a full-length RSV F protein, conferred protection against 
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RSV in a monkey model (56). RSV-reinfections appeared to induce pulmonary histopathology in 
mice (47) and in cotton rats (54). A recent study reported that low doses (0.3 -0.03 µg) of post-
fusion or pre-fusion F proteins primes histopathology in cotton rats after challenge despite lung 
viral clearance (20). F VLP and soluble F proteins used in this study were found to be expressed 
mostly in a post-fusion conformation (data not shown).  We observed that mice prime or prime-
boost immunization with RSV F protein vaccines displayed severe lung histopathology around the 
airways, blood vessels, and interstitial spaces as well as mucus production and eosinophil 
infiltration compared to naïve mice, which is correlating with weight loss disease after RSV 
challenge.  In contrast, F VLP prime only or prime-boost vaccination could prevent pulmonary 
histopathology lower than that in naïve mice after RSV challenge, which are consistent with the 
results in cotton rats (57).  
Comparative studies of F VLP and F protein vaccination might provide insight into 
underlying mechanisms by which RSV vaccine-enhanced disease could be avoided, which will 
help in developing a safe and effective RSV vaccine.  F VLP raises IgG2a Th1 type dominant 
antibodies whereas F protein IgG1 Th2 type dominant responses. These results are consistent with 
cytokine patterns in lung and BALF samples where the F VLP group induced Th1 type (IFN-γ) 
cytokine and the F protein group elicited Th2 (IL-4, IL-5, IL-13) cytokines. Consistent with 
histopathology in the F protein groups, high levels of IL-13 and neutrophil infiltrates due to RSV 
infection were shown to be correlated with mucus production and pathology (58). CD11b+ 
granulocytes and plasmacytoid DCs infiltrating into the lungs after RSV challenge were suggested 
to contribute to RSV disease (59, 60). Lung and BAL T cell intracellular cytokine staining flow 
cytometry assay revealed that F VLP vaccination resulted in higher ratios of IFN-γ/IL-4 CD4 and 
IFN-γ/IL-4 CD8 T cells than F protein vaccination. Naïve mice with live RSV infection also 
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displayed similarly high ratios of IFN-γ/IL-4 CD4 and IFN-γ/IL-4 CD8 T cells although cell 
numbers of T cells secreting IFN-γ were lower than the F VLP group. F VLP vaccination appears 
to induce Th1 bias T cell responses. Induction of Th1 responses including the production of IFN-
γ may modulate to suppress priming Th2 responses such as IL-4, IL-5, and IL-13 responsible for 
RSV pathology.  The F VLP group induces higher levels of IFN-γ and CD8 T cells expressing 
IFN-γ compared to F protein vaccination. These humoral and cellular immunity and antiviral IFN-
γ cytokines induced by F VLP vaccination might have contributed to a better control of lung viral 
loads in addition to neutralizing antibodies. 
Previous studies explored RSV vaccine formulations with immune-modulating adjuvants 
and reported improved efficacy and safety of an intranasal virosomal RSV vaccine adjuvanted 
with monophosphoryl lipid A (61). In contrast, cotton rats immunized with the combination of F 
protein and oligodeoxynucleotide CpG adjuvant developed enhanced pulmonary histopathology 
after RSV challenge (23). Also, a squalene-based emulsion adjuvant mixed with RSV F protein 
vaccine was not able to avoid RSV vaccine-enhanced inflammatory disease and inclusion of 
glucopyranosyl lipid A (TLR4 agonist) modulated to prime IFN-γ producing T cell responses (50). 
RSV subunit vaccines of recombinant pre-fusion or post-fusion F proteins at low doses (<0.3 µg) 
were shown to prime immune responses enhancing lung histopathology regardless of a Th1- or 
Th2-biasing adjuvant in cotton rats after challenge (20). Mice vaccinated with Vac-G or FI-RSV 
and treated with a natural killer T cell activating adjuvant (α-GalCer) or live RSV vaccine plus 
delta-inulin adjuvant did not diminish lung histopathology after RSV challenge (62, 63). 
Interestingly, addition of F VLP to F protein vaccination was found to improve protective efficacy 
and to suppress F protein vaccine-enhanced lung histopathology in infant age mice (data not 
shown). It is important to determine whether F VLP with Th2 bias immune inducing adjuvant will 
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result in vaccine enhanced disease. Therefore, further studies are required to better understand the 
detail mechanisms of RSV vaccine-enhanced disease and to develop a safe and effective RSV 
vaccine.   
To obtain insight into what reactions are occurring at the site of vaccine injection, we analyzed 
acute cytokine, chemokine, and cellular phenotypes at day 1 after IP injection. F VLP injection 
induced transiently chemokines (KC, MCP-1, and RANTES) and IFN-γ. Whereas, F protein 
injection developed Th2 cytokines (IL-4, IL-5, and IL13). Monocyte chemoattractant protein-1 
(MCP-1/CCL2) is known to regulate migration and infiltration of monocytes/macrophages (64). 
RANTES (regulated on activation normal T cell expressed and secreted), now known to be 
secreted by hematopoietic and non-hematopoietic cell types including epithelial cells, acts as a 
chemoattractant for monocytes, natural killer cells, T cells, eosinophils, and dendritic cells as well 
as for maintaining antiviral CD8 T cells (65). F VLP injection resulted in acutely inducing cellular 
infiltrates such as monocytes, neutrophils, and natural killer (NK) cells. The levels of these innate 
acute inflammatory cells appeared to be lower than those reported in previous studies on adjuvants 
such as oil-in-water emulsion MF59 and combination AS04, alum + monophosphoryl lipid A 
(MPL, a TLR4 ligand) (66). These intrinsic differences between F VLP and F protein in generating 
inflammatory microenvironment might be contributing to developing differential quality of 
immunity responsible for enhancing or preventing RSV vaccine-associated disease.  
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4 CHAPTER 2. A UNIQUE COMBINATION ADJUVANT MODULATES IMMUNE 
RESPONSES PREVENTING VACCINE-ENHANCED PULMONARY 
HISTOPATHOLOGY AFTER A SINGLE DOSE VACCINATION WITH FUSION 
PROTEIN AND CHALLENGE WITH RESPIRATORY SYNCYTIAL VIRUS 
 
4.1 Summary 
Alum adjuvanted formalin-inactivated respiratory syncytial virus (RSV) vaccination 
resulted in enhanced respiratory disease in young children upon natural infection, which has been 
a major obstacle in developing a safe and effective RSV vaccine. Here, we investigated the 
adjuvant effects of monophosphoryl lipid A (MPL) and oligodeoxynucleotide CpG (CpG) on 
vaccine-enhanced respiratory disease after fusion (F) protein prime vaccination and RSV challenge 
in infant and adult mouse models in comparison with alum adjuvant.  Combination CpG+MPL 
adjuvant in RSV F protein single dose priming of infant and adult age mice was found to promote 
the induction of IgG2a isotype antibodies and neutralizing activity, and lung viral clearance after 
challenge.  Importantly, CpG+MPL adjuvant F protein priming of infant and adult age mice was 
effective in avoiding lung histopathology, interleukin-4+ CD4 T cell responses, and cellular 
infiltration of monocytes and neutrophils after RSV challenge. There were differential adjuvant 
effects of MPL and CpG on modulating histopathology and inflammatory immune responses, 
depending on the ages of mice at the time of F protein priming.  This study indicates that 
combination CpG and MPL adjuvant in RSV subunit vaccination might contribute to priming 
protective immune responses and preventing inflammatory RSV disease after infection.   
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4.2 Results 
 
4.2.1 Combination CpG+MPL adjuvant in RSV F protein vaccination mediates the effective 
induction of IgG2a antibody and neutralizing activity in infant and adult mice.  
Purified RSV A2 F glycoproteins used in this study were found to be highly reactive to 
post-fusion F specific 131-2a monoclonal antibody (mAb) and site II epitope recognizing 
Palivizumab but poorly reactive to the pre-fusion specific 5C4 mAb (Supplementary Fig. 4.1), 
suggesting that F proteins are mostly in a post-fusion conformation. We reasoned that F proteins 
would serve as a model antigen to test the adjuvant effects on the efficacy and lung inflammatory 
disease after subunit F vaccination and RSV challenge.  Infant (2weeks old) and adult (5~6 weeks 
old) mice were intramuscularly prime immunized with RSV F protein (Fp, 0.1µg) or in the 
presence of alum (50 µg), low dose CpG (4µg), MPL (1µg) or combination CpG (4µg)+MPL 
(1µg) adjuvant (Fig. 4.1). Substantial levels of RSV F specific antibodies were induced after 
vaccination with F proteins in the presence of adjuvants from the mice that were primed at 2-week 
age although higher levels of RSV F specific antibodies were observed in the mice primed at adult 
age (Fig. 4.1A). Combination CpG+MPL adjuvant in F protein vaccination was more effective in 
increasing IgG antibodies than the MPL or CpG alone F protein vaccine group, and similar to those 
in the Alum adjuvant group. IgG1 isotype antibodies were highly induced in the alum adjuvanted 
group whereas higher levels of IgG2a were induced in the CpG, MPL, and CpG+MPL groups (Fig. 
4.1B, C). Adult mice induced higher levels of IgG2a isotype antibodies than those in infant age 
mice in response to CpG, MPL, and CpG+MPL adjuvanted F protein vaccination (Fig. 4.1C). In 
particular, the CpG+MPL F protein groups induced the highest levels of IgG2a isotype antibodies 
in primed infant and adult mice (Fig. 4.1C). Next, we determined whether adjuvants would 
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promote the induction of IgG antibodies recognizing pre-fusion conformation-stabilized F protein 
with DsCav mutations (67). It is notable that CpG+MPL adjuvanted F protein vaccination induced 
IgG antibodies specific for DsCav pre-F antigen at higher levels than alum, CpG, or MPL 
adjuvanted F protein vaccine groups particularly after priming of mice at an infant age (Fig. 4.1D).    
Adult mice showed approximately 2-fold higher levels of RSV neutralizing antibody titers 
than those in infant mice after prime immunization with adjuvanted F proteins (Fig. 4.2A). The 
CpG+MPL F protein group showed highest RSV neutralizing antibody titers among the adjuvanted 
F protein vaccination groups in infant mice. RSV neutralizing antibody titers were similarly high 
in both alum and CpG+MPL adjuvant F protein adult mice (Fig. 4.2A). These data indicate that 
combination CpG+MPL adjuvant in RSV F protein single vaccination effectively induces IgG2a 
antibodies and neutralizing activity in infant and adult mice.  
 
4.2.2 Combination CpG+MPL adjuvant improves lung viral clearance and protection of F 
protein vaccine. 
Protective efficacy of adjuvanted F proteins at 3 weeks after single vaccination was 
assessed by determining lung virus titers after RSV challenge.  Both young age (5 weeks old) and 
adult (8-9 weeks old) naïve mice showed high lung viral titers at day 5 after RSV infection (104 
PFU/ g lung tissues, Fig 4.2B, C).  In the F protein primed groups at an infant age, the CpG+MPL 
group was most effective in clearing lung viral loads by 100 folds, whereas the alum, CpG, and 
MPL groups showed 10 – 20 folds lower RSV titers compared to the equivalent age naïve mice 
(Fig. 4.2B).  In the adult age F protein primed groups, the CpG+MPL group was most effective in 
clearing lung viral loads by 100 folds, followed by the alum, CpG, and MPL groups (Fig. 4.2C). 
Adjuvants F protein primed mice at adult age were more effective in clearing RSV lung viral titers 
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than adjuvanted F protein primed mice at an infant age (Fig 4.2B, C), which is consistent with IgG 
antibody levels (Fig. 4.1).  Overall, combination CpG+MPL adjuvant was more effective than 
other adjuvants in improving the protective efficacy after a single dose F protein vaccination at 
infant or adult ages.    
 
4.2.3 CpG+MPL adjuvant suppresses lung histopathology after F protein vaccination and 
RSV challenge. 
After RSV challenge week 3 post vaccination, alum adjuvanted F protein vaccination of 
mice at infant ages resulted in high PAS positive mucus production in the airway epithelium and 
inflammation scores in the lung histology when examined day 5 post RSV challenge (Fig. 4.3A). 
Also, age matching infected naïve mice displayed significant inflammation histology in the 
airways (scores 1.5), blood vessels (1.3) and interstitial spaces (1.0) compared to those from 
uninfected mice (Fig. 4.3B, C).  We found lower levels of inflammation in the lung histology from 
CpG or MPL adjuvanted RSV F protein immunized mice after RSV challenge compared to those 
in F protein alone or alum adjuvanted RSV F protein vaccine mice (Fig. 4.3B, C). Similar to infant 
age primed mice, the Fp+Alum primed adult group displayed the highest level of PAS+ mucus 
production, followed by F protein and naïve mice (Fig. 4.3D). Infant age mice (Fig. 4.3A, B, C) 
with CpG adjuvant F protein prime was found to be more effective in suppressing inflammation 
in the lung histology (airways, blood vessels, interstitial spaces) than adult age mice with CpG F 
protein prime (Fig. 4.3D, E, F).  Interestingly, MPL appeared to be more effective in suppressing 
lung inflammatory for adult mice (Fig. 4.3D, E, F) with F protein vaccination than CpG although 
there is no statistical difference between the 2 groups. Most notably, in both infant and adult (Fig. 
4.3) age mice with CpG+MPL adjuvanted F protein prime vaccination, lung inflammatory 
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histopathology and PAS positive mucus production in the airway epithelium were not observed 
after RSV challenge. 
We carried out H&CR staining of lung histology as a measure of eosinophilic infiltration 
in the airways at 5 days after RSV challenge (Fig. 4.4).  Both CpG+MPL adjuvanted RSV F primed 
infant (Fig. 4.4A, B) and adult (Fig. 4.4E, F) age mouse groups did not show eosinophil 
infiltrations after RSV challenge, which is similar to naïve mice without RSV infection. In contrast, 
alum adjuvant in F protein vaccination exhibited high levels of eosinophilic H&CR+ staining cell 
spots, followed by naïve mice with RSV infection (Fig. 4.4A, B, E, F). The CpG F protein primed 
adult mice showed a low to moderate level of eosinophilic staining and infiltration, compared to 
those in the MPL F protein primed mice (Fig. 4.4E, F).   
To quantitate eosinophil infiltration, BAL and lung cells from immunized mice were 
collected day 5 post challenge and Siglec F+ eosinophils were determined by flow cytometry 
staining (Fig. 4.4C, D, G, H).  In consistent with the results from H&CR staining of lung histology, 
MPL or CpG +MPL adjuvanted RSV F immunized group showed the lowest level or no 
eosinophils (Fig. 4.4C, D, G, H). The F protein only or CpG adjuvant F protein primed adult mice 
showed a moderate level of eosinophils (Fig. 4.4G, H). In overall, the mice primed with F protein 
at an infant age showed lower infiltrated eosinophils in the BAL airways than the mice primed at 
an adult age, whereas lung eosinophils were approximately 3-fold higher in infant age Fp+Alum 
primed mice than those in adult age Fp+Alum primed mice, after RSV challenge (Fig. 4.4C, G).  
Taken together, these results suggest that CpG+MPL adjuvanted F protein vaccination suppresses 
inflammatory mucus production, lung histopathology, and eosinophil infiltration after RSV 
challenge in infant and adult age mouse models.  
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4.2.4 CpG+MPL adjuvanted F protein priming of infant and adult mice effectively prevents 
the induction of IL-4+ CD4 T cells after RSV challenge.  
To determine whether adjuvants such as alum, CpG and MPL would modulate IFN-ɤ or 
IL-4 producing T cell responses, BAL and lung cells at 5 days after challenge week 3 post prime 
vaccination were analyzed by intracellular cytokine staining flow cytometry after stimulation with 
a known CD4 T cell epitope F51-66 (Fig. 4.5). Both groups of infant and adult age mice primed 
with alum adjuvanted F protein showed the highest levels of CD4 T cells secreting IL-4 cytokines 
in BAL and lung samples (Fig. 4.5A, B). CpG or MPL adjuvant F protein primed mice induced 
relatively low levels of BAL IL-4+ CD4 T cells but these Fp+CpG and Fp+MPL groups displayed 
3- to 4-fold higher levels of lung IL-4+ CD4 T cells than those in FP+C+M group (Fig. 4.5A, B). 
The lowest cellularity of IL-4+ CD4 T cells was observed in BAL and lung samples from infant 
age-primed and adult age-primed mice with combination CpG+MPL adjuvant F proteins (Fig. 
4.5A, B). The CD4 T cell numbers secreting cytokines were higher in adult primed mice than 2-
week old infant age primed mice as presented in different Y axis scales (Fig. 4.5). The mice that 
were primed with CpG+MPL adjuvant F protein at 2 weeks old responded to induce BAL and lung 
IFN-ɤ+ CD4 T cells at 1.5- to 2-fold higher levels than PBS, F protein, alum, CpG, and MPL 
groups after RSV infection (Fig. 4.5A). The groups of CpG and CpG+MPL but not alum adjuvant 
F protein primed mice at an adult age induced IFN-ɤ+ CD4 T cells after challenge (Fig. 4.5B).  
These results suggest that CpG+MPL adjuvanted F protein prime vaccination effectively prevents 
the induction of IL-4+ CD4 T cells, while promoting the induction of IFN-ɤ+ CD4 T cells after 
RSV challenge. 
The Fp+alum group of mice primed at adult age responded with higher levels of Th2 type 
cytokines (IL-4, IL-5, IL-13) by adjuvanted F protein compared to those in the Fp+alum group 
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primed at an infant age after RSV challenge as presented in different Y axis scales (Fig. 4.6A, B). 
The Fp+CpG, Fp+MPL, and Fp+CpG+MPL groups showed relatively low levels of Th2 type 
cytokines but high levels of Th1 cytokine IFN-γ, which were more prominent in the adult age 
primed mice than those in infant age primed mice (Fig. 4.6A, B). 
 
4.2.5 Monocytes and Neutrophils are not infiltrated into the lungs from CpG+MPL 
adjuvanted F protein primed infant and adult mice after RSV challenge 
We analyzed the cellular infiltrates in the airway BAL fluids day 5 post challenge by flow 
cytometry using phenotypic markers of monocytes (CD11b+Ly6chiF4/80+) and neutrophils 
(CD11b+Ly6c+F4/80−) (Fig. 4.7). Fp+alum priming of infant age mice induced highest levels of 
monocytes and neutrophils in BAL fluids, whereas CpG+MPL adjuvant F protein priming of infant 
mice avoided the cellular infiltrates of monocytes and neutrophils after RSV challenge (Fig. 4.7A).  
MPL adjuvant F protein priming was more effective than CpG adjuvant F protein priming in 
preventing the cellular infiltrates of particularly airway monocytes (Fig. 4.7). In F protein priming 
of adult age mice, CpG+MPL adjuvant was most effective in reducing the infiltrates into the 
airways and lungs compared to alum, CpG, and MPL (Fig. 4.6B). Overall, priming vaccination of 
adult mice induced higher cellular infiltrates than infant age primed mice approximately by 4 folds 
as presented in different Y axis scales (Fig. 4.7). These results suggest that CpG+MPL adjuvanted 
F protein priming is effective in avoiding inflammatory cellular infiltrates of monocytes and 
neutrophils into the lungs in infant and adult age mice after challenge. 
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Figure 4. 1. F protein prime vaccination of infant and adult age mice with Alum, CpG, MPL or CpG+MPL 
adjuvants elicits different IgG isotype antibodies. 
 
  
 
 
 
 
 
 
Infant (2 weeks old) or adult (5~6weeks old) BALB/c mice (N=5) were intramuscularly primed with F protein or F 
protein with Alum, CpG, MPL or CpG+MPL and sera were collected 3 weeks after prime. The levels of IgG 
isotypes were determined using a post-fusion F antigen (BEI NR-28908, A, B, C) or pre-fusion DsCav F protein 
antigen (D). PBS: unimmunized mice, F protein: 0.1 µg of F protein, Fp+Alum: F protein 0.1 µg with alum 50 µg, 
Fp+CpG: F protein 0.1 µg with CpG 4 µg, Fp+MPL 1 µg: F protein 0.1 µg with MPL, Fp+C.+M.: F protein 0.1 µg 
with CpG 4 µg and MPL 1 µg combination adjuvants. Results are presented as mean ± SEM. Statistical 
significances were performed by one-way ANOVA in GraphPad Prism; *** p<0.001, ** p<0.01, * p<0.05 
comparing F to F + adjuvant in mice. 
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Figure 4. 2 Neutralizing titers in primed mice and lung viral clearance after challenge. 
 
 
 
 
 
 
 
 (A) Neutralization titers at 3 weeks after prime vaccination of 2 weeks (2wks) old and adult mice. An 
immunoplaque assay was used to determine neutralizing titers and a linear line indicates detection limit. (B-C) 
Lung RSV titers after challenge. PBS (naïve R.) and immunized mice were intranasally (i.n.) challenged with 
3.5x10⁵ PFU RSV A2. BALB/c mice (N=5) were immunized with F protein and F protein with alum, CpG, MPL 
or CpG+MPL. Individual lungs were collected at 5 days after RSV challenge and RSV titers were determined by 
an immunoplaque assay. The linear line represents the lower limit of detection (LLOD). Naïve R: Unvaccinated 
naïve mice with RSV infection. The group labels are the same as in the Figure 1 legend.  Results are presented as 
mean ± SEM. Statistical significances were performed by one-way ANOVA in GraphPad Prism; *** p<0.0001. 
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Figure 4. 3. Lung histopathology and mucus production in primed infant and adult mice after RSV challenge.  
Lung tissue histopathology of the mice primed at 2 weeks (2wks) old (A-C) or at 5-6 weeks old adult age (D-F) at 
5 days after RSV challenge. (A, D) Periodic-Schiff (PAS) stained lung tissues from individual mice (N=5) were 
dissected to assess peribronchiolar, alveolar pneumonia, and mucus production. Photographs of PAS. Scale bars 
indicate 100μm. The percentage of PAS stained lung section area that were PAS positive for each airway was 
determined; individual airways are shown per group. (B, C, E, F) Hematoxyline and Eosin (H&E) stained lung 
tissue were dissected to assess peribronchiolar, alveolar pneumonia. Photographs of H&E. Scale bars indicate 100 
μm. (C, F) The inflammation scores of histopathology were blindly scored using a 1-3 scoring system where 1= 
minimal pathology and 3 = maximum pathology for airway, interstitial spaces, blood vessels. Naïve R: 
Unvaccinated naïve mice with RSV infection. The group labels are the same as in the Figure 1 legend.  Results 
are presented as mean ± SEM. Statistical significances were performed by one-way ANOVA in GraphPad Prism; 
*** P<0.0001, ** p<0.005, * p<0.05. 
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 Figure 4. 4 Eosinophilic infiltration into the lungs of adjuvanted F protein primed infant and adult mice 
after RSV challenge. 
The eosinophil infiltration in hematoxyline and congo red (H&CR) stained sections of individual lung tissue of 
the mice (N=5) primed at 2 weeks old (A) or at 5-6 weeks old adult age (E) at 5 days after RSV challenge. Scale 
bars indicate 400 μm. (B, F) The eosinophils per field infiltration were quantified in the airways. (B) Eosinophil 
granulocytes in the endometrium from infant age (2 weeks old) primed mice after challenge. (E) Eosinophil 
granulocytes in the endometrium in adult mice after RSV challenge. (C, D, G, H) Populations and numbers of 
Siglec F eosinophils gated from granulocytes (CD11b F4/80 CD45) at day 5 post challenge as determined by 
flow cytometry in BAL fluids and Lung tissues. Arrows: eosinophil granulocytes, individual airways were shown 
per group. Results are presented as mean ± SEM. Statistical significances were performed by one-way ANOVA 
in GraphPad Prism; *** p<0.0001, * p<0.05.  
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Figure 4. 5. IL-4 and IFN-γ secreting CD4 ⁺ T cells in BAL and lung samples of infant and adult age primed 
mice after RSV challenge. 
 
Figure 4. 6. Cytokines in the BALF from the primed mice at infant and adult age after RSV challenge. 
BALF and lung cells from infant (A) and adult (B) age primed mice (n=5) were collected at 5 days after challenge. 
CD4 ⁺ T cell epitope peptide F
51−66
 was used to stimulate BALF and lung cells in vitro, which were stained with 
phenotypic marker and cytokine antibodies, and subsequently analyzed by Flowcytometry. The group labels are 
the same as in the legends of Figures 1 and 2. The results are presented as means the SEM, and statistical 
significance was determined using one-way ANOVA with Tukey’s multiple comparison test performed in 
GraphPad Prism. ***, p < 0.0001, **p<0.005, * p<0.05.  
Airway BALF samples were collected from the primed mice (N=5) at infant age (A) and adult age (B) at 5 days 
after RSV challenge.  IL-4, IL-5, IL-13 and IFN-γ cytokines in BALF were determined by corresponding cytokine 
ELISA kits. Results are presented as mean ± SEM. Statistical significances were performed by one-way ANOVA 
and Tukey’s multiple-comparison test in GraphPad Prism; *** p<0.0001, **p<0.001, *p<0.05. The Fp +/- 
adjuvanted vaccination group labels are the same as in the legends of Figures 1 and 2. 
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Figure 4. 7 Monocytes and neutrophils in the airways (BALF) of the infant and adult age primed mice after RSV 
challenge. 
 
 
 
 
 
 
Airway BALF samples were collected from the primed mice (N=5) at infant age (A) and adult age (B) at 5 days 
after RSV challenge, stained with antibodies against monocyte and neutrophil cell type phenotypic markers, 
and analyzed by flow cytometry.  Results are presented as mean ± SEM. Statistical significances were 
performed by one-way ANOVA and Tukey’s multiple-comparison test in GraphPad Prism; *** p<0.0001, 
**p<0.001, *p<0.05. The Fp +/- adjuvanted vaccination group labels are the same as in the legends of Figures 
1 and 2. 
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4.3 Discussion 
It is a challenge to develop safe non-live RSV subunit vaccines due to the potential safety 
concerns of enhanced inflammatory disease in RSV negative populations after RSV infection. 
Subunit vaccines are in general considered to be safer than live virus vaccines. RSV F protein 
subunit nanoparticle vaccines were shown to be safe and immunogenic in adults in clinical 
studies (68, 69). Nonetheless, F protein vaccines were reported to cause vaccine-enhanced lung 
histopathology in animal models after challenge (14, 20-23). Also, in previous studies, vaccine-
associated inflammatory histopathology was not attenuated by inclusion of various adjuvants 
tested, including alum, squalene oil-in-water emulsion (50), TLR4 agonist glucopyranosyl lipid 
A (GLA) integrated into stable emulsion (SE) (20), polysaccharides-based delta-inulin (63), 
natural killer (NK) T cell agonist α-GalCer (62). Also, we found that RSV F protein vaccination 
of mice in the presence of AddaVax squalene oil-in-water emulsion adjuvant, polysaccharides 
fucoidan, and TLR3 agonist poly I:C adjuvants did not suppress lung histopathology after RSV 
challenge despite adjuvant effects on enhancing the immunogenicity of F protein vaccine (data 
not shown).  In this study, we have investigated the adjuvant effects of MPL and CpG on 
immunogenicity, the efficacy of lung viral titers, and particularly on suppressing pulmonary 
histopathology after F protein single dose priming of infant and adult age mice and RSV 
challenge. It is significant to find that combined CpG+MPL adjuvanted F protein priming of 
infant and adult age mice was effective in avoiding lung histopathology, IL-4+ CD4 T cell 
responses, and cellular infiltration of monocytes and neutrophils after RSV challenge, as well as 
enhancing RSV neutralizing antibodies and lung viral clearance. Results in this study suggest 
that combined CpG and MPL adjuvanted RSV subunit vaccination might be effective in priming 
protective immune responses and preventing inflammatory lung pathology after RSV infection.  
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In the RSV F protein vaccination of mice, CpG adjuvant dose of 1 – 20 µg was shown to 
display moderate effects on enhancing IgG2a Th1 type antibody induction (37).  Combination of 
alum (100 µg) + CpG (20-100 µg) adjuvants in F protein vaccination was reported to increase 
neutralization titers, Th1 and Th2 immune responses, and lung viral clearance (37).  Triple 
components of adjuvant CpG (10 µg) with an innate defense regulator peptide in 
polyphosphazene microparticles in the RSV F protein vaccination of mice mediated the 
induction of IgG1 and IgG2a antibodies, resulting in controlling virus replication and no 
evidence of vaccine-induced pathology after challenge (22, 70).  The outcomes of CpG adjuvant 
appear to be different in other studies. CpG in a polysaccharide adjuvant derived from delta 
inulin promoted the induction of predominately IgG2a antibodies to RSV whole virus 
vaccination of mice but exacerbated lung pathology after RSV challenge (63).  Cotton rats that 
were immunized with F protein + CpG (20 - 100 µg) adjuvant increased the induction of 
neutralizing activity titers but developed enhanced pulmonary pathology consisting of alveolitis 
and interstitial pneumonitis after RSV challenge (23). We examined TLR agonist adjuvant 
effects on F protein prime vaccination of mice at infant and adult ages.  CpG (4 µg) adjuvant 
effects on suppressing lung pathology after RSV challenge were found to be prominent in F 
protein primed mice at an infant age. In consistent with these studies (23, 63), CpG + F protein 
priming of mice at adult age resulted in substantial inflammation scores in lung histology, and 
infiltration of eosinophils, monocytes and neutrophils after RSV challenge despite of inducing 
IgG2a Th1 type immune responses.  
TLR4 agonist MPL included in the alum adjuvanted FI-RSV vaccination was 
demonstrated to reduce the polymorphonuclear leukocyte infiltration within the alveoli and 
moderately attenuate peribronchiolitis in cotton rats post-challenge (71).  RSV F protein 
59 
formulated with MPL (15 - 50 µg) administered to cotton rats via intranasal prime and 
intradermal boost demonstrated no evidence of enhanced lung pathology upon RSV infection 
(72).  Inclusion of MPL in the FI-RSV vaccination was found to mitigate the lung pathology 
with a dramatic reduction in levels of Th1- and Th2-type cytokines and chemokines (73). MPL 
analog TLR4 agonist (GLA) in stabilized emulsion adjuvanted F protein vaccination (GLA-SE) 
of BALB/c mice induced Th1-biased humoral and cellular responses including CD4 and CD8 T 
cells, and minimal to moderate levels of eosinophilic infiltration similar to live RSV infection 
control upon RSV challenge (50). In a follow up study, postfusion or prefusion F protein low 
dose (0.03 µg) vaccination of cotton rats even in the presence of a TLR4 agonist Th1-biasing 
(GLA-SE) adjuvant was reported to prime inflammatory vaccine-enhanced alveolitis although 
lung viral titers were below the detection limit after RSV challenge (20).  In this study 
comparing MPL or CpG adjuvant effects on RSV F protein vaccination were similarly effective 
in suppressing histopathology and eosinophil infiltration at moderately low levels in infant age 
primed mice. In adult age priming of mice with F protein, MPL was more prominent in 
suppressing histopathology compared to CpG after RSV challenge although there was no 
statistically difference between the two adjuvants.  In consistent with previous studies (20, 23, 
50, 63), separate MPL or CpG adjuvant alone in F protein priming of mice at infant and adult age 
exhibited a certain degree of histopathology and monocyte infiltration upon RSV challenge, 
despite the induction of Th1 type immune responses and significant reduction in lung viral titers.  
MPL as a TLR4 ligand likely triggers MyD88-dependent (TIRAP/MyD88) and 
TRAM/TRIF (Toll-interleukin 1 receptor domain–containing adapter)-dependent pathways, 
leading to activation of nuclear factor (NF)-κB and IFN-response factor 3 (IRF3) and inducing 
type 1 IFN innate immune responses (74, 75). Intracellular TLR9 ligand CpG interaction recruits 
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MyD88-dependent pathway leading to the activation of NF-κB and IRF7, eventually inducing 
inflammatory cytokines and type 1 IFNs (74). A previous study reported that MPL+CpG 
combination was more effective in inducing IL-12p70 and TNF-α in bone marrow-derived DC 
cultures in vitro than either one alone (66). Synergistic effects of combination TLR4 and 9 agonists 
on IL-1β production but not on IL-6 were demonstrated with stimulation of peripheral blood 
mononuclear cells isolated from healthy adults (76). The mechanisms of combination CpG+MPL 
adjuvant effects on RSV F protein priming remains to be determined.  Inclusion of CpG+MPL in 
the RSV F protein single dose priming of infant and adult age mice was most prominent for 
avoiding lung histopathology, IL-4+ CD4 T cell responses, and cellular infiltration of monocytes 
and neutrophils after RSV challenge, in addition to increasing protective efficacy of lung viral 
clearance after challenge.  The levels of IFN-γ+ CD4 T cells were similarly observed in F protein 
primed infant age mice that displayed different degrees of histopathology, suggesting that an 
inverse correlation between IFN-γ+ CD4 T cells and histopathology is not always predicted.  In 
contrast, priming adult mice with alum adjuvanted F protein showed a typical pattern of high IL-
4+ CD4 T cells and low IFN-γ+ CD4 T cells, which is correlating with inflammatory histopathology 
after RSV challenge. 
 
 
 
 
61 
5 CHAPTER 3. EFFECTS OF NOVEL COMBINATION ADJUVANTS ON 
IMPROVING THE EFFICACY OF INACTIVATED SPLIT RESPIRATORY 
SYNCYTIAL VIRUS VACCINE IN MICE 
 
5.1 Summary 
Human respiratory syncytial virus (RSV) causes severe disease of pneumonia and 
bronchiolitis leading to hospitalizations and mortality of over 160,000 pediatric deaths worldwide. 
There is no licensed vaccine on the market despite extensive effort on developing a safe and 
effective RSV vaccine for several decades. Alum adjuvanted formalin-inactivated whole RSV 
vaccine (FI-RSV) failed in clinical trials in young children due to vaccine-enhanced pulmonary 
disease, which is also recapitulated in animal models. In this study, we investigated the antigenicity 
and immunogenicity of whole FI-RSV and split RSV vaccines, as well as the adjuvant effects on 
improving RSV vaccine efficacy and modulating immune responses that prevent vaccine-
enhanced pulmonary histopathology after vaccination and RSV infection in infant age mice. We 
found that inactivated and detergent-split RSV (SRSV) vaccines expose neutralizing epitopes 
reactive to palivizumab at higher levels than inactivated whole virus. Split RSV vaccination of 
mice induced more desirable immune responses towards T helper type 1 (Th1) and less lung 
histopathology compared to FI-RSV after RSV challenge. Next, we tested the efficacy and 
pulmonary histopathology after Split or FI-RSV vaccination in the presence of alum salts, MPL 
TLR 4 agonist, CpG TLR 9 agonist, or combination MPL+CpG adjuvants. We used 2 weeks old 
infant or adult BALB/c mouse models after prime vaccination and RSV challenge.  Low dose 
combination of MPL + CpG adjuvants was found to be most effective in increasing Th1 type IgG 
antibodies, neutralizing activity, and lung viral clearance as well as modulating balanced immune 
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responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study 
demonstrates adjuvant candidates that would improve the efficacy and safety of subunit RSV 
vaccines. 
 
5.2 Results 
 
5.2.1 Split RSV displays high antigenic reactivity and a unique pattern of immunogenicity in 
adult mice 
RSV was inactivated using formalin and used as whole virus FI-RSV. An additional 
procedure of splitting FI-RSV (Split RSV) was carried out by treatment with non-ionic detergent 
Triton X-100 and resulting split RSV named “split”. Antigenic properties were determined using 
post-fusion F conformation specific monoclonal antibody (mAb) 131-2a, the site II F neutralizing 
epitope specific mAb palivizumab, and pre-fusion F specific 5C4 mAb (Fig. 5.1). Split displayed 
significantly higher levels of reactivity against 131-2a and palivizumab mAbs compared to whole 
virus FI-RSV (Fig. 5.1). Both FI-RSV and Split showed low reactivity against 5C4 mAb, 
suggesting that 5C4 mAb specific pre-fusion epitopes were not well exposed in FI-RSV and split 
RSV vaccine preparations.  
To compare the immunogenicity, adult BALB/c mice (n=5, 8-12 weeks old) were 
intramuscularly immunized with Split (5 µg) and FI-RSV (5 µg) in the absence of adjuvant (Fig. 
5.2). The split group showed a trend of inducing higher levels of RSV specific IgG antibodies than 
the FI-RSV group at 3 weeks after prime vaccination, but the differences were not significant 
between the two groups. Interestingly, split RSV vaccination induced lower IgG1 and higher 
IgG2a isotype antibody levels compared to those after FI-RSV vaccination, and these differences 
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are statistically significant (Fig. 5.2A-C). These results suggest that split RSV displays high 
antigenic reactivity and can induce a unique pattern of immunogenic properties of inducing IgG2a 
isotype antibodies. 
 
5.2.2 Split RSV prime dose controls lung viral loads and attenuates histopathology after RSV 
challenge in adult mice 
To determine the efficacy of split RSV, immunized mice were challenged with RSV at 3 
weeks after prime vaccination (Fig. 5.2).  The whole FI-RSV immunized group showed substantial 
weight loss (~8-13%) at days 3 and 4 after challenge (Fig. 5.2D).  The split RSV immunized group 
displayed approximately 7% weight loss at day 2 after RSV challenge, similar to the unimmunized 
naïve mice after RSV infection.  The naïve mice after RSV infection showed the highest levels of 
viral loads in the lung at day 5 after challenge. Split RSV prime vaccination led to lowering lung 
viral loads by 100, which was comparable to or more effective than FI-RSV prime reducing lung 
viral loads by approximately 30-50 (Fig. 5.2E). 
To determine whether split RSV vaccine would protect against RSV infection and attenuate 
histopathology inflammation responses, histology tissues with infiltrated eosinophils and mucus-
producing cells were visualized in the airway stained by Hematoxylin and eosin stain (H&E), 
hematoxylin and congo red (H&CR) and periodic acid-Schiff (PAS) stain (Fig. 5.3). The split RSV 
vaccine group showed the expression of the murine mucus in the lung as quantified (Fig. 5.3C, F). 
However, eosinophils and numerous PAS-positive airway epithelial cells were seen in the lung 
from FI-RSV immune mice compared to those in split RSV immune mice after infection with RSV 
(Fig. 5.3B, E). Overall, these results indicate that RSV infection in split RSV immune mice showed 
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much less histopathology responses, including the inflammation and mucus induction that was 
typically seen with FI-RSV immune mice with RSV respiratory infections. 
 
5.2.3 CpG and MPL adjuvants in split RSV prime vaccination promotes IgG2a isotype 
dominant antibody responses in infant age mice 
Young children are a more prime target for effective and safe RSV vaccination than adults.  
We tested whether CpG and MPL adjuvants in split RSV prime vaccination would promote 
desirable Th1 type (IgG2a) immune responses and the efficacy of protection preventing enhanced 
RSV disease in 2 weeks old infant mice after challenge.  Infant age (2weeks old) BALB/c mice 
were prime (single dose) immunized with whole FI-RSV (2 µg), split RSV (2 µg) alone, or split 
RSV adjuvanted with alum (50 µg), MPL (1 µg, TLR4 agonist), CpG (4 µg, TLR9 agonist), or 
MPL (1 µg) + CpG (4 µg). At 3 weeks after single dose vaccination, sera were collected and used 
to measure IgG and isotype antibodies specific for RSV antigens (Fig. 5.4A-C). Both FI-RSV and 
Split RSV prime vaccination of infant mice induced IgG antibodies specific for RSV at a 
comparable level. Alum and CpG+MPL adjuvant groups induced higher IgG antibody responses 
compared to FI-RSV or Split RSV alone (Fig. 5.4A). Higher levels of IgG1 isotype dominant 
antibodies were induced in the FI-RSV alone and split RSV+alum groups than those in split alone 
or CpG, MPL alone or combination CpG+MPL adjuvanted groups which showed relatively high 
levels of IgG2a isotype antibodies (Fig. 5.4B, C).  
Next, we determined IgG antibodies specific for purified post-fusion F, pre-fusion F, and 
G130-230 fragment antigens since RSV preparations might have host cell-derived proteins. The 
split+alum, split+MPL, and split+CpG+MPL groups induced higher levels of IgG antibodies 
specific for post-fusion and pre-fusion F protein antigens (Fig. 5.4D, E). Overall, IgG antibodies 
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specific for post-fusion F were induced at higher levels than those for pre-fusion F. The split+Alum 
group induced IgG binding to G130-230 at higher levels than other groups (Fig. 5.4E). F specific 
antibodies were induced at higher levels in vaccinated groups than G130-230 antibodies.  
 
5.2.4 Alum and combination CpG+MPL adjuvants are effective in enhancing RSV 
neutralizing activity and controlling lung viral loads after RSV challenge 
Palivizumab of RSV F-specific neutralizing monoclonal antibody has been licensed as a 
prophylactic drug. Thus, induction of neutralizing antibodies after RSV vaccination can be a key 
protective immune correlate against RSV.  The FI-RSV and split RSV groups showed 4- to 8-fold 
increases in RSV neutralizing titers in sera compared to unimmunized control at 3 weeks after 
single dose vaccination of infant age mice (Fig. 5.5A). The split+CpG and split+MPL groups did 
not display increases in neutralizing titers compared to split vaccine alone. Alum and combination 
CpG+MPL adjuvants in split RSV vaccination of infant age mice enhanced RSV neutralizing titers 
by 2- to 3-fold compared to the split alone group (Fig. 5.5A).  
To determine protective efficacy at 5 weeks after single dose split RSV vaccination of 
infant age mice, control naïve and vaccinated mice were intranasally challenged with RSV A2 
(3.5x10⁵ PFU) (Fig. 5.5B). The groups of mice primed with whole FI-RSV or split RSV at 2 weeks 
old exhibited approximately 10-20 folds lower lung RSV titers than those in unvaccinated mice as 
determined day 5 post challenge after sacrifice of mice (Fig. 5.5B) Moderate reduction in lung 
RSV titers by about 7-8 folds was observed in the split+CpG and split+MPL groups compared to 
the split vaccine alone group. The split plus combination CpG+MPL group was the most effective 
in reducing lung viral titers by over 50-fold, followed by split+alum vaccination compared to the 
split alone group (Fig. 5.5B), which is consistent with RSV neutralization titers.    
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5.2.5 CpG+MPL in split RSV vaccination of infant age mice prevents lung histopathology 
after RSV Challenge 
When lung histology was examined day 5 post challenge at 5 weeks after priming, the 
whole FI-RSV alone primed mice at infant age displayed more severe alveolitis in the airways than 
unimmunized mice or split RSV alone primed mice (Fig. 5.6A, B), substantial inflammation in the 
around blood vessels, perivascular, and interstitial spaces (Fig. 5.6A, C, D). The split RSV alone 
primed mice at infant age exhibited less severe histopathology than whole FI-RSV priming or 
naïve mouse with RSV infection (Fig. 5.6). The alum adjuvant in split RSV priming of infant mice 
resulted in enhancing histopathology whereas the split+CpG and split+MPL groups did not show 
significant histological changes compared to the spit RSV alone group, displaying local infiltration 
of cells in the alveolar space and interstitial space (Fig. 5.6).  Priming of infant mice with split 
RSV plus CpG+MPL resulted in most effectively preventing histopathological inflammation in 
the airways, blood vessels, perivascular, and interstitial spaces compared to other vaccine and 
control groups (Fig. 5.6). 
We further analyzed the presence of PAS positive mucus production and H&CR positive 
eosinophilic infiltration in the histology (Fig. 5.6E, F). Split RSV alone priming of infant age mice 
resulted in significantly lower levels of mucus production and eosinophilic infiltration than whole 
FI-RSV priming (Fig. 5.6E, F).  The addition of combination CpG+MPL but not alum, CpG, or 
MPL adjuvant to the split RSV priming of infant mice further attenuated mucus production and 
eosinophilic induction. Overall, these results suggest that CpG+MPL combination adjuvant in split 
RSV vaccination of infant age mice contributes to preventing lung histopathology after RSV 
Challenge.   
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5.2.6 CpG and MPL adjuvants in split RSV vaccination of infant age mice primes Th1 type 
immune responses in spleen cells  
Spleen cells collected day 5 post challenge from RSV vaccine-primed mice were cultured 
to determine in vitro IgG antibody and cytokine production (Fig. 5.7). The FI-RSV alone and split 
RSV +/- alum groups showed high levels of RSV specific IgG1 antibodies in splenocyte culture 
supernatants, whereas the split RSV with CpG+MPL group secreted higher levels of IgG2a isotype 
antibodies in vitro (Fig. 5.7B, C). We also determined IL-4 and IFN-γ cytokine levels secreted in 
culture supernatants splenocyte stimulated with CD8 T cell epitopes (F85-93: KYKNAVTEL, F92-
106: ELQLLMQSTPATNNR) (Fig. 5.7D, E). Spleen cells from the FI-RSV alone and Split RSV 
+/- alum groups produced high levels of IL-4 and low levels of IFN-γ cytokines.  In contrast, spleen 
cells from the split+CpG, split+MPL, or split with CpG+MPL group secreted lower levels of IL-
4 and higher levels of IFN-γ cytokines in culture supernatants compared to the split RSV alone 
group. 
 
5.2.7 Split RSV with CpG and MPL promotes Th1 T cells and cytokines in lung and BALF 
after challenge  
Cells in lung tissues and BALF collected from RSV-vaccinated mice at day 5 after challenge were 
in vitro cultured in the presence of F51−66 CD4 T cell epitope or F85-93 epitope for CD8 ⁺ T cells and 
analyzed by intracellular cytokine staining (Fig. 5.8). The FI-RSV alone and split RSV +/- alum 
groups showed relatively high numbers of BALF and lung IL-4+ CD4 T cells, TNF-α CD8 T cells 
and moderate levels of IFN-γ+ CD4 and CD8 T cells. Split+CpG and Split+MPL immune mice 
displayed low BALF IL-4+ CD4 T cells but moderate levels of both IL-4+ and IFN-γ+ CD4 T 
cells in lung tissue samples.  In contrast, split RSV plus combination CpG+MPL immune mice 
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exhibited low numbers of IL-4+ CD4 T cells and high numbers of IFN-γ+ CD4 T cells in both 
lung tissue and BALF samples.  These results suggest that CpG+MPL adjuvanted split RSV 
vaccination effectively prevents the induction of IL-4+ CD4 T cells and TNF-α CD8 T cells, while 
promoting the induction of IFN-ɤ+ CD4 and CD8 T cells after RSV challenge. To better 
understand histopathology, the pattern of Th1- and Th2-type cytokines was measured in lung 
homogenates by ELISA at 5 days after RSV challenge in the immunized mice (Fig. 5.9). The split 
RSV group showed lower levels of IL-4, IL-5, and IL-13 cytokines in lung homogenates and 
airway BALF than those in the FI-RSV alone or split+alum group after challenge although not all 
cytokines were statistically significant as indicated (Fig. 5.9A, B, C).  Combination CpG+MPL in 
split RSV vaccination was found to be more effective in suppressing lung and BALF Th2 cytokines 
(IL-4, IL-5, IL-13) and promoting Th1 IFN-γ cytokine than CpG or MPL alone after RSV 
challenge.  
 
5.2.8 Split RSV-primed mice with CpG + MPL prevents infiltrating inflammatory immune 
cells into the lung after RSV challenge   
Cellular phenotypes of infiltrates into the respiratory tracts were determined 5 days after RSV 
challenge by flow cytometry (Fig 5.10). Lower levels of monocytes (CD11b+Ly6chighF4/80+) in 
BALF were observed in the groups of Split, Split+ CpG, and split with CpG+MPL than 
Split+alum, Split+MPL, and FI-RSV groups (Fig 10A), although their differences were not 
significant in lung samples (Fig 5.10F).  Neutrophils (CD11b+Ly6c+F4/80-) in BALF and lung 
samples were detected at lower levels in the Split alone, split+CpG, and split with CpG+MPL 
immune mice compared to those in the split+Alum, Split+MPL, and FI-RSV group day 5 post 
RSV challenge (Fig. 5.10B, G). Also, eosinophils (CD11b+CD11c+SiglecF+) in BALF were 
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found at the lowest levels in the split with CpG+MPL immune mice, followed by the split+CpG 
and split+MPL groups (Fig 5.10C).  The split+CpG and split+MPL did not reduce the levels of 
lung eosinophils compared to that in the split alone group (Fig 5.10H).  Interestingly, subsets of 
dendritic cells (pDC; CD11c+B220+MHCIIhigh and CD103+DC; CD11c+MHCII+F4/80-CD11b-
CD103+DCs) were found to be at the highest levels in BALF and lung samples compared with 
other groups (Fig. 5.10 D, E, I, J). Monocytes derived DCs play a role in regulating T cell immunity 
by producing Th1 or Th2 cytokines upon antigen uptake and presentation (59). 
 
 
Figure 5. 1. Antigenic properties of whole FI-RSV and split RSV vaccines.  
The antigenic properties of whole FI-RSV and split RSV vaccines were analyzed by ELISA using post-fusion 
conformation epitope specific monoclonal antibody (mono-F, 131-2a), site II epitope specific antibody 
palivizumab, and pre-fusion conformation epitope specific monoclonal antibody 5C4.  
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Figure 5. 2. Split RSV vaccination induces higher levels of IgG2a isotype antibodies and better protection 
against RSV than FI-RSV vaccine in adult mice.  
 
BALB/c mice (N=4- 5 and 6-8weeks old) were immunized with FI-RSV and Split RSV. Sere were collected 3 
weeks after prime vaccination. (A-C) IgG and IgG isotype antibodies response after prime immunization. The 
IgG isotypes levels were detected using RSV as an ELISA antigen for antibody detection. Naive: unimmunized 
mice-No RSV challenge, FI-RSV: FI-RSV immunized mice, Split: Split RSV immunized mice.  (D) Body 
weight changes in prime immunized mice after RSV challenge. (E) RSV titers at day 5 after RSV challenge. 
Individual lungs were collected day 5 post challenge with RSV and RSV titers were determined. Naïve R.: 
unimmunized mice with RSV infection, FI-RSV: FI-RSV immunized mice with RSV challenge, Split: Split 
RSV immunized mice with RSV challenge. Naïve and immunized mice were i.n. challenged with 3.5x10⁵ PFU 
RSV A2.  Results are presented as mean ± SEM. Statistical significances were performed by one-way ANOVA 
in GraphPad Prism; *** p<0.001, ** p<0.01, * p<0.05 comparing FI-RSV to split + Adjuvants, Split RSV to 
Split RSV with adjuvants in mice. 
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Figure 5. 3. Lung histopathology in single immunized adult mice after RSV challenge.  
 
 
 
 
 
Individual lung tissues were collected from immunized mice day 5 post RSV challenge (3.5x10
5 
PFU/mouse) and analyzed by histology. (A) H&E staining of lung tissues. Scale bars for H&E indicate 100 
μm. (B) H&CR staining to determine pulmonary eosinophil in each mouse lung airway. Scale bars for 
H&CR indicate 20μm.  (C) PAS stained tissue sections from PAS positive area in bronchioalveolar (10 
individual airways in each mouse).   (D) H&E stained tissue sections from each mouse were scored for 
inflammation on a scale of 0 to 3 as diagnostic criteria. Inflammation scores around airways, blood vessels 
and interstitial spaces.  (E) Pulmonary eosinophils per 40× field counts in two different regions of each 
mice. (F) Mucus production by PAS stained area was quantitated and represented as percentage. Results 
are presented as mean ± SEM. Statistical significances were calculated by 1-way ANOVA and Tukey’s 
multiple comparison test. *; p<0.05, **; p<0.01, and ***; p<0.001.  
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Figure 5. 4. RSV antigen specific IgG and isotype antibody levels in infant age mice after prime immunization. 
 
Figure 5. 5. RSV neutralizing activity titers in primed-mice at an infant age and lung viral loads after RSV 
challenge.  
 
Infant (2weeks old) age mice (N=5) were single immunized with FI-RSV or Split RSV in the presence or absence 
of adjuvant (Alum, CpG, MPL or CpG+MPL adjuvants).  RSV antigen specific IgG and isotype antibody levels 
were determined by ELISA at 3 weeks after prime immunization. (A) IgG antibodies specific for FI-RSV, (B) 
IgG1 isotype antibodies specific for FI-RSV, (C) IgG2a isotype antibodies specific for FI-RSV, (D) Post-fusion 
F protein specific IgG antibodies, (E) Pre-fusion F protein specific IgG antibodies, (F) RSV A2 G protein fragment 
(aa131-230) specific IgG antibodies. Naive: unimmunized mice, FI-RSV: formalin inactivated RSV (2 µg), Split: 
Formalin inactivated split RSV (5µg), Split+Alum: Split RSV (5 µg) with alum (50 µg), Split+CpG: split RSV (5 
µg) with CpG (4 µg), Split+MPL: Split RSV (5 µg) with MPL (1 µg), Split+C.+M.: Split RSV (5 µg) with CpG 
(4 µg) and MPL (1 µg) combination adjuvants. Results are presented as mean ± SEM. Statistical significances 
were performed by one-way ANOVA in GraphPad Prism; *** p<0.001, ** p<0.01, * p<0.05 comparing FI-RSV 
to split + Adjuvants, Split RSV to Split RSV with adjuvants in mice. 
Infant age (2 weeks old) mice (N=5) were prime immunized and sera were collected at 3 weeks after prime 
vaccination. (A) Serum neutralizing antibody titers are expressed as the reciprocal of the highest serum dilutions 
giving 50% reduction of plaque numbers relative to the medium controls. (B) Lung RSV titers after challenge. 
Naïve R.: unimmunized mice with RSV infection, FI-RSV: FI-RSV immunized mice with RSV challenge, Split: 
Split RSV immunized mice with RSV challenge. Naïve and immunized mice were i.n. challenged with 3.5x10⁵ 
PFU RSV A2. Split+Alum: split RSV (5 µg) with alum (50 µg), Split+CpG: split RSV (5 µg) with CpG (4 µg), 
Split+MPL: split RSV (5 µg) with MPL (1 µg), Split+C.+M.: split RSV (5 µg) with CpG (4 µg) and MPL (1 µg) 
combination adjuvants. Individual lungs were collected at 5 days after RSV challenge and RSV titers were 
determined by an immunoplaque assay. The dot line is the limit of detection (LOD). Results are presented as mean 
± SEM. Statistical significances were performed by one-way ANOVA in GraphPad Prism; *** p<0.0001, ** 
p<0.01, * p<0.05. 
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Figure 5. 6. Histopathology of Hematoxylin Eosin (H&E), Periodic acid-Schiff (PAS) staining of lung tissues in 
split RSV primed mice at an infant age after RSV challenge.  
 
 
Figure 5. 7. CpG+MPL adjuvant split RSV primed mice at an infant age induce IgG2a-secreting cells and IFN-
γ secreting splenocytes after RSV challenge.   
  
 
 
Individual lung tissues were collected from prime vaccinated BALB/c mice (N=5) at 2-week old day 5 post 
challenge. In addition, the mice that were immunized with FI-RSV were used for the positive control of pulmonary 
inflammation. (A) Photographs of H&E. Hematoxyline and Eosin (H&E) stained lung tissues were dissected to 
assess histopathology of peribronchiolar and alveolar pneumonia. Scale bars indicate 100 μm. (B-D) The lungs were 
scored using a 0-3 scoring system (0= absent, 1= minimal pathology and 3 = maximum/severe pathology) for the 
alveolitis (B), perivascular region (C), interstitial region (D). (E) Photographs and percentage for PAS positive 
pulmonary mucus production Scale bars indicate 100 μm. (F) Photographs and score for eosinophil infiltration in 
alveolitis with hematoxyline and congo red (H&CR) stained lung tissue at 5 days after RSV challenge. Scale bars 
indicate 400μm. Arrows: eosinophil granulocytes, individual airways were shown per group. Results are presented 
as mean ± SEM. Statistical significances were performed by one-way ANOVA in GraphPad Prism; *** P<0.001, 
** p<0.01, * p<0.05. Groups are the same as described in the Fig. 5. 
 (A-C) RSV specific IgG and isotype antibody secreting cell responses were determined after in vitro cultures of 
spleen cells from split RSV primed mice at an infant age day 5 post RSV challenge. (A) IgG, (B) IgG1 and (C) 
IgG2a levels were detected by ELISA using FI-RSV as a coating antigen. (D, E) Th1 or Th2 cytokine responses 
were determined after in vitro cultures of spleen cells collected day 5 post RSV challenge.  Spleen cells (1x10
6
/ml) 
were stimulated with peptide F
51−66
 epitope for CD4 T cells or F
85-93
 epitope for CD8 T cells for 36hr. Culture 
supernatants of splenocytes were used to determine cytokines of IL-4 (D) and IFN-γ (E) by ELISA analysis.  Results 
are presented as mean ± SEM. Statistical significances were performed by one-way ANOVA and Tukey’s multiple-
comparison tests in GraphPad Prism; *** p<0.0001, **p<0.001, *p<0.05. Groups are the same as described in the 
Fig. 5. 
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Figure 5. 8. Intracellular cytokine staining of CD4 and CD8 T cells of BALF and lung samples after RSV 
challenge.  
 
 
 
 
 
 
 
 
BALF (A, B, C, D) and lung (E, F, G, H) cells were collected from primed mice at 2weeks old day 5 post challenge 
and subjected to intracellular cytokine staining. Sorted cells were analyzed by Flowcytometry after in vitro 
stimulation with F
51−66
 epitopes for CD4 ⁺ T cell (A, B, E, F) and F
85-93
 epitopes for CD8 ⁺ T cell (C, D, G, H). The 
results are presented as means the SEM, and statistical significance was determined using one-way ANOVA with 
Tukey’s multiple comparison test performed in GraphPad Prism. ***, p < 0.0001, **p<0.005. Groups are the same 
as described in the Fig. 5. 
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Figure 5. 9. Th1- and Th2- cytokine levels in lung homogenates and BALF from split RSV primed mice at an 
infant age after RSV challenge. 
 
 
Day 5 post RSV challenge (3.5x10⁵ PFU), individual lung tissue (A, B, C, D, E, F) and BALF (G, H, I, J, K, L) 
samples were collected from split RSV primed mice at an infant age (N=5).  IL-4, IL-5, IL-6, IL-13, IFN-γ and 
TNF-α cytokine levels in lung homogenates and BALF samples were determined by ELISA. Results are 
presented as mean ± SEM. Statistical significances were performed by one-way ANOVA and Tukey’s multiple-
comparison test in GraphPad Prism; *** p<0.0001, **p<0.001, *p<0.05. Groups are the same as described in 
the Fig. 5. 
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Figure 5. 10. Cellular phenotypes of infiltrates into BALF and lung tissues of split RSV primed mice at an infant 
age after RSV infection. 
 
 
5.3 Discussion 
Since the tragic failure of alum-adjuvanted whole FI-RSV vaccine in young children in 
1960s, safety concerns have been raised regarding the non-replicating RSV subunit vaccines that 
are likely to cause enhanced respiratory disease particularly in RSV naïve infants after exposure 
to live RSV. Therefore, RSV subunit vaccines mostly based on purified F proteins have been 
targeted to the elderly or pregnant women for maternal immunization. In contrast to RSV, 
inactivated detergent-split influenza virus subunit vaccines are licensed for vaccination in different 
age populations including 6 months old age infants, children, adults, and the elderly, and most 
prevalently used for seasonal vaccination against influenza.  We found that inactivated detergent-
split RSV vaccines expose neutralizing epitopes reactive to palivizumab at higher levels than 
inactivated whole FI-RSV. Split RSV vaccination of adult mice induced more desirable immune 
responses towards Th1 type IgG antibodies and less lung histopathology compared to FI-RSV after 
RSV challenge. In an infant mouse model, inclusion of combination CpG+MPL adjuvants in the 
split RSV prime vaccination further improved the efficacy of split RSV vaccines and, more 
importantly, prevented pulmonary histopathology after RSV challenge. This study demonstrates a 
Phenotypes of cellular infiltrates in BALF (A, B, C, D, E) and lung (F, G, H, I, J) samples were analyzed by 
Flowcytometry.  Monocytes: D11b+Ly6chighF4/80+ (A, F), Neutrophils; CD11b+Ly6c+F4/80- (B, G), 
Eosinophil; CD11b+SiglecF+ (C, H), pDC; CD11c+B220+MHCII
High
 (D, I), cDC; CD11c+MHCII+F4/80-CD11b-
CD103+DCs (E, J) data were shown as mean ± SEM. Statistical significances were calculated by 1-way ANOVA 
and Tukey’s multiple comparison test. *; p<0.05, **; p<0.01, and ***; p<0.001 as indicated among the groups. 
Groups are the same as described in the Fig. 5. 
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different view on inactivated split RSV vaccination in contrast to whole FI-RSV and adjuvant 
effects on preventing inflammatory disease after RSV challenge in an infant mouse model.   
In clinical trials of influenza virus vaccines in adults (35), inactivated whole-virus vaccines were 
reported to induce an increase in reactogenicity than split subvirion vaccines, which was 
prominently observed in naïve populations. Fevers were more frequently observed after 
vaccination with whole-virus than split-product vaccine especially in naive children one to four 
years old, but fevers related with vaccination were less likely in primed children (34).  A single 
dose of whole-virus vaccine was shown to be more immunogenic than split-virus vaccine in the 
unprimed adults.  In naïve children (<10 years old), split-product vaccine induced less 
hemagglutination-inhibiting antibodies than whole-virus vaccine (34). Therefore, split influenza 
virion vaccines are less reactogenic and induce lower rates of sero-conversion compared with 
inactivated whole-virus vaccines in naïve hosts (77) but similarly immunogenic in primed 
individuals (35). Clinical effectiveness of split-virion vaccines was significantly higher than 
purified-protein subunit trivalent influenza vaccines in older adults (78). Long history of safety 
and efficacy data on split-virion influenza vaccines provides attractive rationales for developing 
split-RSV vaccine candidates.  Split RSV was found to be more reactive to 131-2a and palivizumab 
mAbs, suggesting a possibility that splitting RSV might have induced conformation changes 
exposing post-fusion and site II neutralizing epitopes to be more reactive for antibodies. 
Unexpectedly, higher levels of Th1 type IgG2a were induced after prime dose of split RSV, and 
less weight loss and lower lung viral loads in split RSV-primed adult mice after RSV challenge 
compared to those in whole FI-RSV. In particular, it is highly desirable to observe that 
histopathology in the airways, blood vessels, and interstitial spaces as well as the levels of mucus 
production and H&CR+ eosinophilic spots were significantly attenuated in split RSV primed adult 
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mice after RSV challenge compared to those in whole FI-RSV and unimmunized naïve control 
with RSV infection. In a relevant previous study, nanoemulsion-based inactivated RSV intranasal 
vaccination of mice induced high levels of Th1/Th17 responses and protection without causing 
Th2 immune mediated pathology after RSV challenge (36). 
Vaccine-enhanced respiratory disease was observed in naïve young children after 
vaccination and natural RSV infection (6). Vaccine-associated inflammatory histopathology was 
not attenuated by RSV vaccines in squalene oil-in-water emulsion (50) or with natural killer T cell 
agonist α-GalCer (62). As focused in this study, it is significant to determine the adjuvant effects 
on improving the efficacy of split RSV vaccines and on preventing inflammatory lung 
histopathology after RSV challenge in an infant mouse model. Consistent with a pattern of IgG 
isotype antibodies after prime vaccination of adult mice, split RSV induced a balanced IgG1 and 
IgG2a antibodies in contrast to whole FI-RSV inducing IgG1 dominant antibodies after prime dose 
in infant age mice.  FI-RSV but not split RSV vaccination of infant mice in the absence of adjuvant 
resulted in causing substantial histopathology after challenge, which is consistent with the 
histology observed in adult mice. Alum adjuvant in split RSV vaccination of infant age mice 
enhanced the neutralizing activity titers and lung viral clearance as well as histopathology. These 
results are in line with the studies of alum adjuvant effects on RSV vaccination.  Inclusion of alum 
adjuvant in the FI-RSV or F protein subunit vaccination contributed to vaccine-enhanced 
respiratory disease in mice after RSV challenge (59, 79). 
Previous studies on adjuvant effects on RSV vaccination were reported with different outcomes. 
CpG adjuvant in RSV F protein vaccination was reported to exhibit moderate effects on enhancing 
IgG2a isotype antibodies, but detail lung histopathology was not investigated (37).  
Polyphosphazene microparticle formulations containing RSV F proteins, an innate defense 
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peptide, and CpG adjuvant were able to induce Th1 type immune responses and lung viral 
clearance after RSV challenge although histopathology was not reported (22, 70).  Combination 
of CpG and delta inulin adjuvant in whole RSV vaccination induced IgG2a antibodies in mice but 
exacerbated lung pathology after RSV challenge (63). Combination alum+MPL in FI-RSV 
vaccination was shown to moderately attenuate peribronchiolitis in cotton rats post-challenge (71).  
Post-fusion or pre-fusion F protein in TLR4 analog in stable emulsion vaccine formulation was 
reported to prime inflammatory vaccine-enhanced alveolitis in cotton rats although lung viral titers 
were below the detection limit after RSV challenge (20). In this study, combination CpG+MPL in 
split RSV vaccination was relatively effective in increasing IgG and IgG2a as well as in clearing 
lung viral loads after challenge compared with CpG (4 µg), MPL (1 µg) alone adjuvant groups. 
The Split+CpG and Split+MPL groups did not significantly improve lung histopathology 
compared with split RSV alone vaccination after challenge.  The combination CpG+MPL group 
was more effective in inducing IFN-γ+ CD4 and CD8 T cells in BALF and lung tissues after 
challenge than the CpG or MPL adjuvant groups. Whereas, IL-4 producing CD4 T cells were most 
effectively suppressed in both BALF and lung tissues, compared with the split alone, or CpG or 
MPL adjuvanted split groups.  Also, IL-4, IL-5 and IL-13 cytokines were detected in BALF from 
the CpG+MPL group at the lowest levels of background similar to uninfected naïve mice whereas 
substantial levels of these Th2 cytokines were observed with the alum, CpG or MPL adjuvanted 
split groups.  
The split plus CpG+MPL group was less likely to recruit inflammatory innate cells of monocytes, 
neutrophils, and eosinophils in BALF compared to MPL or eosinophils in BALF and lungs 
compared to CpG adjuvant after RSV challenge. Instead, CD103+ dendritic cells (DC) were 
recruited into BALF and lungs at higher levels after RSV challenge compared to MPL or CpG 
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adjuvant group.  The TLR9 CpG signaling is mainly dependent on the MyD88 adaptor pathway 
(80). Whereas, TLR4 ligand signaling is known to involve multiple pathways including TRIF 
(Toll-interleukin 1 receptor domain–containing adapter inducing interferon-β) and TRAM (TRIF-
related adaptor molecule) in addition to MyD88 (81, 82).  Combination MPL + CpG was shown 
to exhibit synergistic and additive effects on producing IL-12p70 and TNF-α respectively during 
bone marrow-derived DC stimulation in vitro, and upregulating CD40 and CD86 markers on DCs 
(41). A previous study also showed that MPL+CpG in vivo treatment recruited lower levels of 
eosinophils and natural killer cells, and natural killer T cells compared to those by CpG or MPL 
(Ko, 2018 AVR).  Further studies are needed to better understand the mechanisms of combination 
CpG+MPL adjuvant effects on attenuating lung pathology after RSV vaccination and challenge.  
In addition, split RSV prime immunization of infant age mice was relatively more effective in 
inducing IFN-γ+ CD4 and CD8 T cells, suppressing IL-4 cytokines and innate inflammatory cells 
in BALF than whole FI-RSV prime after RSV challenge. More studies will be carried out to better 
characterize the antigenic and immunogenic properties between whole FI-RSV and split RSV 
vaccines. This study suggests a possibility that split RSV vaccines with an appropriate selection 
of adjuvants would be developed into an effective and safe vaccine candidate.  
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6 CONCLUSION 
 
RSV infection is responsible for annual outbreaks of lower respiratory tract disease in 
infants and elderly, resulting in global incidence of 33 million cases in children younger than 5 
years old, an estimated 3.4 million hospitalizations, and up to 199,000 deaths (2).  In the US, RSV 
infection is associated with 177,000 hospitalizations and 14,000 deaths in the elderly over 65 years 
old (3).  Inactivated-whole virus FI-RSV vaccines in alum-adjuvanted formulations in the 1960s 
clinical trials failed due to enhancing respiratory disease after RSV season infection (6). Licensed 
RSV vaccines are not available despite numerous efforts to develop effective and safe RSV vaccine 
candidates. One of the challenges in developing RSV vaccines is to induce protective immune 
responses of high RSV neutralizing antibodies but to avoid respiratory disease of inflammatory 
pulmonary histopathology after RSV infection.  My PhD studies have focused on better 
understanding host immune responses after RSV vaccination and virus challenge, the pattern of 
immune responses leading to protection or RSV-disease enhancing inflammation, and the various 
adjuvant effects on modulating vaccine-induced immune responses to avoid pulmonary 
histopathology after RSV challenge infection. Adult and infant age mouse models were used in 
these studies with different platforms of vaccines including RSV F protein, F VLP particulate 
forms produced in insect cells, or whole FI-RSV and split RSV.  
 
6.1 Protective or disease-enhancing immune responses after prime vaccination with 
soluble F protein or particulate F VLP and RSV challenge infection  
In the first project, I investigated the pattern of immune responses to F VLP and soluble 
form fusion (F) protein, and their results on inflammatory disease and efficacy of protection after 
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RSV challenge.  F VLP vaccination of mice induced Th1 type IgG2a dominant antibody response 
but F protein vaccination induced IgG1 isotype dominant antibody responses, representing Th1 
and Th2 type immune patterns respectively. Although prime or prime-boost immunization with F 
VLP and F protein vaccines showed remarkable neutralizing activity and controlling lung viral 
replication after RSV challenge, RSV F protein vaccine immunized mice displayed severe lung 
histopathology as well as mucus production and infiltration of eosinophils compared to F VLP 
vaccine mice which could prevent pulmonary histopathology and lower than that in naïve mice 
after RSV challenge.  
The immunogenicity of F VLP vaccines has been focused on antigen-specific immune 
responses after prime immunization in comparison with prime-boost immunization. F VLP was 
found to be effective in inducing Th1 type IgG2a antibody responses and cytokine (IFN-γ). 
Whereas F protein vaccination with alum adjuvant induced Th2 cytokines (IL-4, IL-5, and IL-13) 
and Th2 type IgG1 isotype antibody responses in both prime and prime-boost immunized mice.  
As a result, there were striking differences in pulmonary histopathology, mucus 
production, and eosinophilia as well as body weight loss of RSV disease between the F VLP and 
F protein vaccine groups of mice. These results suggest that soluble F proteins exacerbate 
pulmonary histopathology after vaccination upon RSV challenge but not when presented on VLP 
particles. An intrinsic property of F VLP to stimulate acute innate immune responses at the site 
of injection appears to be a mechanism responsible for the striking opposite outcomes of 
inducing Th1 type priming immune responses after RSV challenge, preventing RSV vaccine-
enhanced disease between F protein and F VLP vaccine platforms. 
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Table 6. 1 Protection or RSV disease enhancing inflammatory responses by prime 
or prime-boost immunization of RSV vaccines and then RSV challenge infection. 
 
6.2 Effects of adjuvants in RSV F protein vaccination on modulating immune responses  
To development of safe and efficacy vaccines, it is still required to improve the 
protection conferred by RSV vaccines without causing VED. Basically, adjuvants are innate and 
acute immune stimulators and cell-mediated immune response to vaccine antigens on site of 
injection (83). In the second project, I investigated the effects of MPL and CpG adjuvants on 
protective immunity and on modulating host immune responses to F protein vaccination in infant 
and adult mouse models in comparison with alum adjuvant.  Combination CpG+MPL adjuvant 
in RSV F protein single dose priming of infant and adult age mice was found to promote the 
induction of IgG2a isotype antibodies and RSV neutralizing activity, and lung viral clearance 
after RSV challenge infection. The adjuvant effects of CpG or MPL appear to be less effective in 
Low: -/+ 
Moderate: +/++ 
High: +++ 
Severe: ++++ 
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promoting protective immunity and in preventing inflammatory histopathology after F protein 
vaccination and RSV challenge, compared to combination adjuvant.  In contrast, CpG+MPL 
adjuvant together included in F protein priming vaccination was effective in avoiding 
inflammatory lung histopathology, interleukin-4+ CD4 T cell responses, and cellular infiltration 
of monocytes and neutrophils after RSV challenge in both infant and adult age mice. There were 
differential adjuvant effects of MPL and CpG on modulating histopathology and inflammatory 
immune responses, depending on the ages of mice at the time of F protein priming vaccination.  
This study indicates that combination CpG and MPL adjuvant in RSV subunit vaccination might 
contribute to priming protective immune responses and preventing inflammatory RSV disease 
after infection.   
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Table 6. 2 Adjuvants effects on RSV F protein vaccination efficacy and inflammatory 
disease in adult and infant age mice. 
 
6.3 Comparison of whole FI-RSV and inactivated-split RSV vaccines, and adjuvant 
effects on split RSV vaccination in infant age mice. 
Licensed inactivated split influenza vaccine has been known to be safe and efficacious 
for human vaccination even in children over 6 months old. Similarly, RSV split vaccine might be 
a platform of a possible RSV vaccine. It remains unknown whether inactivated split RSV 
vaccination would confer protection with or without causing vaccine-enhanced disease. Studies 
using inactivated split RSV vaccines might reveal similarities and differences with previous FI-
RSV vaccination. As a potential vaccine candidate, split RSV vaccines might provide an 
approach for gaining insights into protective immune correlates. It is also possible that vaccine 
Low: -/+ 
Moderate: +/++ 
High: +++ 
Severe: ++++ 
LLOD: Lower limit of detection 
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adjuvants would modulate immune responses to split RSV vaccination. It is an innovative 
approach to study the adjuvant effects on modulating immune responses to RSV split 
vaccination. 
In the third project, I determined whether inactivated split RSV vaccines would provide 
protection and attenuate pulmonary histopathology after RSV challenge, in comparison with 
whole FI-RSV vaccines in an infant age mouse model.  Also, I determined whether MPL and 
CpG adjuvants would improve the protective efficacy by preventing histopathology of lung 
inflammation after split RSV vaccination and challenge in infant (2 weeks old age) mice.  I 
found that inactivated and detergent-split RSV vaccines expose neutralizing epitopes reactive to 
palivizumab, a licensed drug of monoclonal antibody, at higher levels than inactivated whole 
virus, FI-RSV. Split RSV vaccination of mice induced more desirable immune responses 
towards Th1 type IgG2a antibodies and less lung histopathology compared to FI-RSV after RSV 
challenge.  Next, I tested the efficacy and pulmonary histopathology after a single dose of split 
RSV vaccination in the presence of CpG and MPL adjuvants. Among the adjuvants of alum, 
MPL, and CpG, split RSV prime vaccination of infant age mice with CpG+MPL adjuvant was 
found to be most effective in increasing Th1 type IgG2a antibodies, neutralizing activity, and 
lung viral clearance as well as modulating balanced immune responses to prevent pulmonary 
histopathology after RSV vaccination and challenge.   
88 
Table 6. 3 Comparison of whole FI-RSV and inactivated-split RSV vaccines, and adjuvant 
effects on split RSV vaccination in infant age mice. 
 
Cotton rats have been shown to be more susceptible to RSV infection and an appropriate 
model for the study of RSV pathogenesis and vaccine efficacy (84). In preliminary studies, I also 
investigated the immunogenicity and safety of pulmonary histopathology after split RSV 
vaccination and challenge in a cotton rat model. Preliminary data suggest that inactivated-split 
RSV vaccines would be immunogenic and effective in controlling the lung viral loads in cotton 
rats without causing apparent pulmonary inflammation and histopathology after RSV challenge 
infection. Further studies will be needed in future to determine whether inactivated-split RSV 
vaccines would be developed into a safe and effective RSV vaccine candidate against RSV.   
 In summary, my PhD studies have discovered the following findings contributing to 
advancing RSV vaccine field. (1) Soluble F proteins exacerbate pulmonary histopathology after 
vaccination upon RSV challenge but not when presented on virus-like particles. (2) A 
Low: -/+ 
Moderate: +/++ 
High: +++ 
Severe: ++++ 
LLOD: Lower limit of detection 
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combination of low dose MPL+CpG adjuvant displays significant effects on improving the 
efficacy of soluble F subunit vaccines and preventing pulmonary histopathology after RSV 
challenge in infant and adult mice. (3) Split RSV was found to be more effective in exposing 
neutralizing epitopes and in conferring protection by attenuating lung histopathology compared 
to whole FI-RSV. Inclusion of MPL+CpG adjuvant in split RSV vaccination resulted in 
improving the protective efficacy as well as in modulating immune responses avoiding 
pulmonary histopathology after RSV challenge. 
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